

SEZNAM POUŽITÉ LITERATURY A ZDROJŮ

1. Krejčí D. Knihovna a archiv - Novotvary 2016 ČR a Novotvary 2017 ČR. Accessed November 3, 2022. <https://www.uzis.cz/index.php?pg=vystupy--knihovna&id=372>.
2. Klugar M, Klugarová J, Pokorná A, et al. Metodické postupy pro vytvoření a posuzování nově vytvořených KDP. Published online 2020. https://kdp.uzis.cz/res/file/metodika/metodicke-postupy-pro-vytvoreni-a-posuzovani-nove-vytvorenych-kdp_v2.1.pdf
3. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. *J Clin Oncol*. 2009;27(36):6199-6206.
4. Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. *CA: A Cancer Journal for Clinicians*. 2017;67(6):472-492.
5. American Joint Committee on Cancer. Implementation of AJCC 8th Edition Cancer Staging System. Published online 2017.
6. Bowling J, Argenziano G, Azenha A, et al. Dermoscopy Key Points: Recommendations from the International Dermoscopy Society. *Dermatology (Basel, Switzerland)*. 2007;214:3-5.
7. Malvehy J, Puig S, Argenziano G, et al. Dermoscopy report: Proposal for standardization: Results of a consensus meeting of the International Dermoscopy Society. *Journal of the American Academy of Dermatology*. 2007;57(1):84-95.
8. Menzies S, Zalaudek I, Menzies SW, Zalaudek I. Why perform dermoscopy? The evidence for its role in the routine management of pigmented skin lesions. *Arch Dermatol* 142:1211-1212. *Archives of dermatology*. 2006;142:1211-1212.
9. Menzies SW, Crotty KA, Ingvar C, McCarthy WH. An Atlas of Surface Microscopy of Pigmented Skin Lesions: Dermoscopy, Second Edition. AUSTRLN edition. McGraw-Hill Book Company Australia; 2002.
10. Bafounta ML, Beauchet A, Aegerter P, Saiag P. Is dermoscopy (epiluminescence microscopy) useful for the diagnosis of melanoma? Results of a meta-analysis using techniques adapted to the evaluation of diagnostic tests. *Arch Dermatol*. 2001;137(10):1343-1350.
11. Kittler H, Weitzdorfer R, Pehamberger H, et al. Compliance with follow-up and prognosis among patients with thin melanomas. *European Journal of Cancer*. 2001;37(12):1504-1509.
12. Argenziano G, Puig S, Zalaudek I, et al. Dermoscopy improves accuracy of primary care physicians to triage lesions suggestive of skin cancer. *J Clin Oncol*. 2006;24(12):1877-1882.
13. Benelli C, Roscetti E, Pozzo VD, et al. The dermoscopic versus the clinical diagnosis of melanoma. *Eur J Dermatol*. 1999;9(6):470-476.
14. Bono A, Bartoli C, Cascinelli N, et al. Melanoma detection. A prospective study comparing diagnosis with the naked eye, dermatoscopy and telespectrophotometry. *Dermatology (Basel, Switzerland)*. 2002;205:362-366.
15. Bono A, Tolomio E, Trincione S, et al. Micro-melanoma detection: A clinical study on 206 consecutive cases of pigmented skin lesions with a diameter ≤ 3 mm. *British Journal Dermatology*. 2006;155(3):570-573.
16. Carli P, Mannone F, de Giorgi V, et al. The problem of false-positive diagnosis in melanoma screening: the impact of dermoscopy. *Melanoma Research*. 2003;13(2):179-182.
17. Carli P, de Giorgi V, Chiarugi A, et al. Addition of dermoscopy to conventional naked-eye examination in melanoma screening: a randomized study. *Journal of the American Academy of Dermatology*. 2004;50(5):683-689.
18. Carli P, De Giorgi V, Crocetti E, et al. Improvement of malignant/benign ratio in excised melanocytic lesions in the 'dermoscopy era': a retrospective study 1997-2001. *British Journal of Dermatology*. 2004;150(4):687-692.
19. Cristofolini M, Zumiani G, Bauer P, et al. Dermatoscopy: usefulness in the differential diagnosis of cutaneous pigmentary lesions. *Melanoma Research*. 1994;4(6):391-394.
20. Dummer W, Doehnel KA, Remy W. Videomicroscopy in differential diagnosis of skin tumors and secondary prevention of malignant melanoma. *Hautarzt*. 1993;44(12):772-776.

21. Stanganelli I, Serafini M, Bucchi L. A cancer-registry-assisted evaluation of the accuracy of digital epiluminescence microscopy associated with clinical examination of pigmented skin lesions. *Dermatology (Basel, Switzerland)*. 2000;200(1):11-16.
22. Vestergaard ME, Macaskill P, Holt PE, Menzies SW. Dermoscopy compared with naked eye examination for the diagnosis of primary melanoma: a meta-analysis of studies performed in a clinical setting. *British Journal of Dermatology*. 2008;159(3):669-676.
23. Aitken JF, Barbour A, Burmeister B, et al. Clinical Practice Guidelines for the Management of Melanoma in Australia and New Zealand. Cancer Council Australia; Australian Cancer Network; Ministry of Health, New Zealand; 2008:1-246. Accessed August 18, 2022. <https://espace.library.uq.edu.au/view/UQ:196029>
24. Dolianitis C, Kelly J, Wolfe R, Simpson P. Comparative performance of 4 dermoscopic algorithms by nonexperts for the diagnosis of melanocytic lesions. *Arch Dermatol*. 2005;141(8):1008-1014.
25. Westerhoff K, McCarthy WH, Menzies SW. Increase in the sensitivity for melanoma diagnosis by primary care physicians using skin surface microscopy. *Br J Dermatol*. 2000;143(5):1016-1020.
26. Binder M, Puspoeck-Schwarz M, Steiner A, et al. Epiluminescence microscopy of small pigmented skin lesions: short-term formal training improves the diagnostic performance of dermatologists. *J Am Acad Dermatol*. 1997;36(2 Pt 1):197-202.
27. Benati E, Ribero S, Longo C, et al. Clinical and dermoscopic clues to differentiate pigmented nail bands: an International Dermoscopy Society study. *Journal of the European Academy of Dermatology and Venereology*. 2017;31(4):732-736.
28. Blum A, Simionescu O, Argenziano G, et al. Dermoscopy of pigmented lesions of the mucosa and the mucocutaneous junction: results of a multicenter study by the International Dermoscopy Society (IDS). *Arch Dermatol*. 2011;147(10):1181-1187.
29. Braun RP, Thomas L, Dusza SW, et al. Dermoscopy of acral melanoma: a multicenter study on behalf of the international dermoscopy society. *Dermatology*. 2013;227(4):373-380.
30. Menzies SW, Kreusch J, Byth K, et al. Dermoscopic evaluation of amelanotic and hypomelanotic melanoma. *Arch Dermatol*. 2008;144(9):1120-1127.
31. Ronger S, Touzet S, Ligeron C, et al. Dermoscopic examination of nail pigmentation. *Arch Dermatol*. 2002;138(10):1327-1333.
32. Haenssle HA, Krueger U, Vente C, et al. Results from an observational trial: digital epiluminescence microscopy follow-up of atypical nevi increases the sensitivity and the chance of success of conventional dermoscopy in detecting melanoma. *J Invest Dermatol*. 2006;126(5):980-985.
33. Haenssle HA, Mograby N, Ngassa A, et al. Association of Patient Risk Factors and Frequency of Nevus-Associated Cutaneous Melanomas. *JAMA Dermatol*. 2016;152(3):291-298.
34. Kittler H, Guitera P, Riedl E, et al. Identification of Clinically Featureless Incipient Melanoma Using Sequential Dermoscopy Imaging. *Archives of dermatology*. 2006;142:1113-1119.
35. Robinson JK, Nickoloff BJ. Digital epiluminescence microscopy monitoring of high-risk patients. *Arch Dermatol*. 2004;140(1):49-56.
36. Menzies SW, Gutenev A, Avramidis M, et al. Short-term digital surface microscopic monitoring of atypical or changing melanocytic lesions. *Arch Dermatol*. 2001;137(12):1583-1589.
37. Menzies SW, Emery J, Staples M, et al. Impact of dermoscopy and short-term sequential digital dermoscopy imaging for the management of pigmented lesions in primary care: a sequential intervention trial. *British Journal of Dermatology*. 2009;161(6):1270-1277.
38. Tiersten AD, Grin CM, Kopf AW, et al. Prospective follow-up for malignant melanoma in patients with atypical-mole (dysplastic-nevus) syndrome. *J Dermatol Surg Oncol*. 1991;17(1):44-48.
39. Wang SQ, Kopf AW, Koenig K, et al. Detection of melanomas in patients followed up with total cutaneous examinations, total cutaneous photography, and dermoscopy. *J Am Acad Dermatol*. 2004;50(1):15-20.
40. MacKie RM. Early detection, screening and surveillance for malignant melanoma. A critique of current methods of reducing secondary mortality from malignant melanoma. *Skin Cancer*. 1993;8(4):269-274.
41. Feit NE, Dusza SW, Marghoob AA. Melanomas detected with the aid of total cutaneous photography. *British Journal of Dermatology*. 2004;150(4):706-714.
42. Kelly JW, Yeatman JM, Regalia C, et al. A high incidence of melanoma found in patients with multiple dysplastic naevi by photographic surveillance. *Medical Journal of Australia*. 1997;167(4):191-194.

43. Goodson AG, Florell SR, Hyde M, et al. Comparative analysis of total body and dermatoscopic photographic monitoring of nevi in similar patient populations at risk for cutaneous melanoma. *Dermatol Surg.* 2010;36(7):1087-1098.
44. Tronnier M, Garbe C, Bröcker EB, et al. [Standards in histopathologic diagnosis of malignant melanomas. Recommendations of the Working Group of the Central Malignant Melanoma Registry of the German Dermatologic Society]. *Hautarzt.* 1997;48(10):720-729.
45. Tran KT, Wright NA, Cockerell CJ. Biopsy of the pigmented lesion--when and how. *J Am Acad Dermatol.* 2008;59(5):852-871.
46. Martin RCG, Scoggins CR, Ross MI, et al. Is incisional biopsy of melanoma harmful? *Am J Surg.* 2005;190(6):913-917.
47. Ng JC, Swain S, Dowling JP, et al. The impact of partial biopsy on histopathologic diagnosis of cutaneous melanoma: Experience of an Australian tertiary referral service. *Archives of Dermatology.* 2010;146(3):234-239.
48. Pflugfelder A, Weide B, Eigentler TK, et al. Incisional biopsy and melanoma prognosis: Facts and controversies. *Clin Dermatol.* 2010;28(3):316-318.
49. Stell VH, Norton HJ, Smith KS, et al. Method of Biopsy and Incidence of Positive Margins in Primary Melanoma. *Ann Surg Oncol.* 2007;14(2):893-898.
50. Hunger RE, Seyed Jafari SM, Angermeier S, Shafighi M. Excision of fascia in melanoma thicker than 2mm: no evidence for improved clinical outcome. *British Journal of Dermatology.* 2014;171(6):1391-1396.
51. Sladden MJ, Balch C, Barzilai DA, et al. Surgical excision margins for primary cutaneous melanoma. *Cochrane Database Syst Rev.* 2009;(4):CD004835.
52. Wheatley K, Wilson JS, Gaunt P, Marsden JR. Surgical excision margins in primary cutaneous melanoma: A meta-analysis and Bayesian probability evaluation. *Cancer Treatment Reviews.* 2016;42:73-81.
53. Veronesi U, Cascinelli N. Narrow excision (1-cm margin). A safe procedure for thin cutaneous melanoma. *Arch Surg.* 1991;126(4):438-441.
54. Joyce KM, Joyce CW, Jones DM, et al. An assessment of histological margins and recurrence of melanoma in situ. *Plast Reconstr Surg Glob Open.* 2015;3(2):e301.
55. Kunishige JH, Brodland DG, Zitelli JA. Surgical margins for melanoma in situ. *J Am Acad Dermatol.* 2012;66(3):438-444.
56. McLeod M, Choudhary S, Giannakakis G, Nouri K. Surgical Treatments for Lentigo Maligna: A Review. *Dermatologic Surgery.* 2011;37(9):1210-1228.
57. Moehrle M, Schippert W, Garbe C, et al. Prognostic parameters and surgical strategies for facial melanomas. *JDDG.* 2003;1:457-463.
58. Stevenson O, Ahmed I. Lentigo maligna prognosis and treatment options. *American journal of clinical dermatology.* 2005;6:151-164.
59. Lichte V, Breuninger H, Metzler G, et al. Acral lentiginous melanoma: conventional histology vs. three-dimensional histology. *Br J Dermatol.* 2009;160(3):591-599.
60. Moehrle M, Metzger S, Schippert W, et al. "Functional" Surgery in Subungual Melanoma. *Dermatologic Surgery.* 2003;29(4):366-374.
61. Möhrle M. Micrographic controlled surgery (3D-histology) in cutaneous melanoma. *J Dtsch Dermatol Ges.* 2003;1(11):869-875.
62. Löser C, Rempel R, Breuninger H, et al. Microscopically controlled surgery (MCS). *JDDG.* 2010;8:920-925.
63. Dengel L, Turza K, Noland MMB, et al. Skin Mapping With Punch Biopsies for Defining Margins in Melanoma: When You Don't Know How Far to Go. *Ann Surg Oncol.* 2008;15(11):3028-3035.
64. Brown CD, Zitelli JA. The prognosis and treatment of true local cutaneous recurrent malignant melanoma. *Dermatol Surg.* 1995;21(4):285-290.
65. Cohen LM, McCall MW, Hodge SJ, et al. Successful treatment of lentigo maligna and lentigo maligna melanoma with mohs' micrographic surgery aided by rush permanent sections. *Cancer.* 1994;73(12):2964-2970.
66. Dawn ME, Dawn AG, Miller SJ. Mohs surgery for the treatment of melanoma in situ: a review. *Dermatol Surg.* 2007;33(4):395-402.
67. Dong XD, Tyler D, Johnson JL, et al. Analysis of prognosis and disease progression after local recurrence of melanoma. *Cancer.* 2000;88(5):1063-1071.
68. Testori A, Rutkowski P, Marsden J, et al. Surgery and radiotherapy in the treatment of cutaneous melanoma. *Annals of Oncology.* 2009;20:vi22-vi29.
69. Wornom IL, Smith JW, Soong SJ, et al. Surgery as palliative treatment for distant metastases of melanoma. *Ann Surg.* 1986;204(2):181-185.
70. Young S, Martinez S, Faries M, et al. Can Surgical Therapy Alone Achieve Long-Term Cure of Melanoma Metastatic to Regional Nodes? *Cancer journal (Sudbury, Mass).* 2006;12:207-211.
71. Martinez SR, Young SE. A rational surgical approach to the treatment of distant melanoma metastases. *Cancer Treat Rev.* 2008;34(7):614-620.
72. Schwager S, Leiter U, Buettner P, et al. Management of primary and metastasized melanoma in Germany in the time period 1976-2005: An analysis of the Central Malignant Melanoma Registry of the German Dermatological Society. *Melanoma research.* 2008;18:112-119.
73. Garbe C, Eigentler TK. Therapy of malignant melanoma at the stage of distant metastasis. *Hautarzt.* 2004;55(2):195-213.
74. Keilholz U, Ascierto PA, Dummer R, et al. ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee. *Ann Oncol.* 2020;31(11):1435-1448.
75. Michielin O, van Akkooi ACJ, Ascierto PA, et al. ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. *Ann Oncol.* 2019;30(12):1884-1901.
76. Wong SL, Faries MB, Kennedy EB, et al. Sentinel lymph node biopsy and management of regional lymph nodes in Melanoma: American society of clinical oncology and society of surgical oncology clinical practice guideline update. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology.* 2018;36(4):399-413.
77. Garbe C, Amaral T, Peris K, et al. European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022. *European Journal of Cancer.* 2022;170:256-284.
78. NCCN. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Melanoma: Cutaneous, Version 1.2022 – December 3, 2021. Published online 2022.
79. Farshad A, Burg G, Panizzon R, Dummer R. A retrospective study of 150 patients with lentigo maligna and lentigo maligna melanoma and the efficacy of radiotherapy using Grenz or soft X-rays. *British Journal of Dermatology.* 2002;146(6):1042-1046.
80. Harwood AR. Conventional fractionated radiotherapy for 51 patients with lentigo maligna and lentigo maligna melanoma. *Int J Radiat Oncol Biol Phys.* 1983;9(7):1019-1021.
81. Schmid-Wendtner MH, Brunner B, Konz B, et al. Fractionated radiotherapy of lentigo maligna and lentigo maligna melanoma in 64 patients. *J Am Acad Dermatol.* 2000;43(3):477-482.
82. Seegenschmiedt MH, Keilholz L, Altendorf-Hofmann A, et al. Palliative radiotherapy for recurrent and metastatic malignant melanoma: prognostic factors for tumor response and long-term outcome: a 20-year experience. *International Journal of Radiation Oncology*Biophysics*Physics.* 1999;44(3):607-618.
83. Foote MC, Burmeister B, Burmeister E, et al. Desmoplastic Melanoma: The Role of Radiotherapy in Improving Local Control. *ANZ Journal of Surgery.* 2008;78(4):273-276.
84. Vongtama R, Safa A, Gallardo D, et al. Efficacy of radiation therapy in the local control of desmoplastic malignant melanoma. *Head & Neck.* 2003;25(6):423-428.
85. Rule W, Allred J, Pockaj B, et al. Results of NCCTG N0275 (Alliance) - a phase II trial evaluating resection followed by adjuvant radiation therapy for patients with desmoplastic melanoma. *Cancer medicine.* 2016;5.
86. Chen J, Hruby G, Scolyer R, et al. Desmoplastic neurotropic melanoma: A clinicopathologic analysis of 128 cases. *Cancer.* 2008;113:2770-2778.
87. Arora A, Lowe L, Su L, et al. Wide excision without radiation for desmoplastic melanoma. *Cancer.* 2005;104(7):1462-1467.
88. Stevens G, Thompson JF, Firth I, et al. Locally advanced melanoma. *Cancer.* 2000;88(1):88-94.
89. Storper IS, Lee SP, Abemayor E, Juillard G. The role of radiation therapy in the treatment of head and neck cutaneous melanoma. *American Journal of Otolaryngology.* 1993;14(6):426-431.
90. Ang KK, Peters LJ, Weber RS, et al. Postoperative radiotherapy for cutaneous melanoma of the head and neck region. *Int J Radiat Oncol Biol Phys.* 1994;30(4):795-798.
91. LeBoit PE, Burg G, Weedon D, Sarasin A. Pathology and Genetics of Skin Tumours. Accessed October 26, 2022. <https://publications.iarc.fr/Book-And-Report-Series/Who-Classification-Of-Tumours/Pathology-And-Genetics-Of-Skin-Tumours-2005>
92. Guitart J, Lowe L, Piepkorn M, et al. Histological characteristics of metastasizing thin melanomas: a case-control study of 43 cases. *Arch Dermatol.* 2002;138(5):603-608.

93. Morris KT, Busam KJ, Bero S, Patel A, Brady MS. Primary Cutaneous Melanoma with Regression Does not Require a Lower Threshold for Sentinel Lymph Node Biopsy. *Ann Surg Oncol*. 2008;15(1):316-322.
94. Kashani-Sabet M, Sagebiel RW, Ferreira CM, et al. Vascular involvement in the prognosis of primary cutaneous melanoma. *Arch Dermatol*. 2001;137(9):1169-1173.
95. Yeh I, Bastian BC. Melanoma pathology: new approaches and classification. *Br J Dermatol*. 2021;185(2):282-293.
96. Elder DE, Bastian BC, Cree IA, et al. The 2018 World Health Organization Classification of Cutaneous, Mucosal, and Uveal Melanoma: Detailed Analysis of 9 Distinct Subtypes Defined by Their Evolutionary Pathway. *Arch Pathol Lab Med*. 2020;144(4):500-522.
97. Guhan S, Klebanov N, Tsao H. Melanoma genomics: a state-of-the-art review of practical clinical applications. *Br J Dermatol*. 2021;185(2):272-281.
98. de la Fouchardiere A, Blokx W, van Kempen LC, et al. ESP, EORTC, and EURACAN Expert Opinion: practical recommendations for the pathological diagnosis and clinical management of intermediate melanocytic tumors and rare related melanoma variants. *Virchows Arch*. 2021;479(1):3-11.
99. Sawyer A, McGoldrick RB, Mackey SP, et al. Does staging computerized tomography change management in thick malignant melanoma? *Journal of Plastic, Reconstructive & Aesthetic Surgery*. 2009;62(4):453-456.
100. Yancovitz M, Finelt N, Warycha MA, et al. Role of radiologic imaging at the time of initial diagnosis of stage T1b-T3b melanoma. *Cancer*. 2007;110(5):1107-1114.
101. Xing Y, Bronstein Y, Ross MI, et al. Contemporary Diagnostic Imaging Modalities for the Staging and Surveillance of Melanoma Patients: a Meta-analysis. *J Natl Cancer Inst*. 2011;103(2):129-142.
102. Voit C, Van Akkooi ACJ, Schäfer-Hesterberg G, et al. Ultrasound morphology criteria predict metastatic disease of the sentinel nodes in patients with melanoma. *J Clin Oncol*. 2010;28(5):847-852.
103. Bafounta ML, Beauchet A, Chagnon S, Saiag P. Ultrasonography or palpation for detection of melanoma nodal invasion: a meta-analysis. *Lancet Oncol*. 2004;5(11):673-680.
104. Mocellin S, Zavagno G, Nitti D. The prognostic value of serum S100B in patients with cutaneous melanoma: A meta-analysis. *International Journal of Cancer*. 2008;123(10):2370-2376.
105. Wang TS, Johnson TM, Cascade PN, et al. Evaluation of staging chest radiographs and serum lactate dehydrogenase for localized melanoma. *Journal of the American Academy of Dermatology*. 2004;51(3):399-405.
106. Minn H, Vihinen P. Melanoma imaging with highly specific PET probes: ready for prime time? *J Nucl Med*. 2011;52(1):5-7.
107. Jiménez-Requena F, Delgado-Bolton RC, Fernández-Pérez C, et al. Meta-analysis of the performance of 18F-FDG PET in cutaneous melanoma. *Eur J Nucl Med Mol Imaging*. 2010;37(2):284-300.
108. Krug B, Pirson AS, Crott R, Vander Borcht T. The diagnostic accuracy of 18F-FDG PET in cutaneous malignant melanoma. *Eur J Nucl Med Mol Imaging*. 2010;37(7):1434-1435; author reply 1436-1437.
109. Veit-Haibach P, Vogt F, Jablonka R, et al. Diagnostic accuracy of contrast-enhanced FDG-PET/CT in primary staging of cutaneous malignant melanoma. *European journal of nuclear medicine and molecular imaging*. 2009;36:910-918.
110. Clark PB, Soo V, Kraas J, et al. Futility of fluorodeoxyglucose F 18 positron emission tomography in initial evaluation of patients with T2 to T4 melanoma. *Arch Surg*. 2006;141(3):284-288.
111. El-Maraghi RH, Kielar AZ. PET vs sentinel lymph node biopsy for staging melanoma: a patient intervention, comparison, outcome analysis. *J Am Coll Radiol*. 2008;5(8):924-931.
112. Klode J, Dissemmond J, Grabbe S, Hillen U, Poeppl T, Boeing C. Sentinel lymph node excision and PET-CT in the initial stage of malignant melanoma: a retrospective analysis of 61 patients with malignant melanoma in American Joint Committee on Cancer stages I and II. *Dermatol Surg*. 2010;36(4):439-445.
113. Maubec E, Lumbroso J, Masson F, et al. F-18 fluorodeoxy-D-glucose positron emission tomography scan in the initial evaluation of patients with a primary melanoma thicker than 4 mm. *Melanoma Res*. 2007;17(3):147-154.
114. Singh B, Ezziddin S, Palmedo H, et al. Preoperative 18F-FDG-PET/CT imaging and sentinel node biopsy in the detection of regional lymph node metastases in malignant melanoma. *Melanoma research*. 2008;18:346-352.
115. Revel A, Revel C, Dolivet G, et al. La TEP-TDM au 18FDG a-t-elle un intérêt dans la stadification ganglionnaire des mélanomes malins cutanés cervicofaciaux bénéficiant de la technique du ganglion sentinelle ? À propos de 22 cas. *Médecine Nucléaire*. 2010;34(9):528-539.
116. Ploeg IMC van der, Olmos RAV, Kroon BBR, et al. The yield of SPECT/CT for anatomical lymphatic mapping in patients with melanoma. *Ann Surg Oncol*. 2009;16(6):1537-1542.
117. Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation in melanoma. *N Engl J Med*. 2006;355(13):1307-1317.
118. Valsecchi M, Silbermins D, Rosa N, et al. Lymphatic Mapping and Sentinel Lymph Node Biopsy in Patients With Melanoma: A Meta-Analysis. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2011;29:1479-1487.
119. Leiter U, Buettner PG, Bohnenberger K, et al. Sentinel Lymph Node Dissection in Primary Melanoma Reduces Subsequent Regional Lymph Node Metastasis as Well as Distant Metastasis After Nodal Involvement. *Ann Surg Oncol*. 2010;17(1):129-137.
120. Satzger I, Meier A, Hoy L, et al. Sentinel Node Dissection Delays Recurrence and Prolongs Melanoma-Related Survival: An Analysis of 673 Patients from a Single Center with Long-Term Follow-Up. *Ann Surg Oncol*. 2011;18(2):514-520.
121. Kretschmer L, Thoms KM, Peeters S, et al. Postoperative morbidity of lymph node excision for cutaneous melanoma-sentinel lymphonectomy versus complete regional lymph node dissection. *Melanoma Research*. 2008;18(1):16-21.
122. Morton DL, Cochran AJ, Thompson JF, et al. Sentinel Node Biopsy for Early-Stage Melanoma: Accuracy and Morbidity in MSLT-I, an International Multicenter Trial. *Annals of Surgery*. 2005;242(3):302-313.
123. Roaten JB, Pearlman N, Gonzalez R, et al. Identifying risk factors for complications following sentinel lymph node biopsy for melanoma. *Arch Surg*. 2005;140(1):85-89.
124. McMasters KM, Wong SL, Edwards MJ, et al. Factors that predict the presence of sentinel lymph node metastasis in patients with melanoma. *Surgery*. 2001;130(2):151-156.
125. Testori A, De Salvo GL, Montesco M, et al. Clinical Considerations on Sentinel Node Biopsy in Melanoma from an Italian Multicentric Study on 1,313 Patients (SOLISM-IMI). *Annals of Surgical Oncology*. 2009;16:2018-2027.
126. Nguyen CL, McClay EF, Cole DJ, et al. Melanoma thickness and histology predict sentinel lymph node status. *The American Journal of Surgery*. 2001;181(1):8-11.
127. Taylor RC, Patel A, Panageas KS, et al. Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma. *J Clin Oncol*. 2007;25(7):869-875.
128. Kretschmer L, Starz H, Thoms KM, et al. Age as a key factor influencing metastasizing patterns and disease-specific survival after sentinel lymph node biopsy for cutaneous melanoma. *International Journal of Cancer*. 2011;129(6):1435-1442.
129. Kunte C, Geimer T, Baumert J, et al. Prognostic factors associated with sentinel lymph node positivity and effect of sentinel status on survival: an analysis of 1049 patients with cutaneous melanoma. *Melanoma Research*. 2010;20(4):330-337.
130. Mays MP, Martin RCG, Burton A, et al. Should all patients with melanoma between 1 and 2 mm Breslow thickness undergo sentinel lymph node biopsy? *Cancer*. 2010;116(6):1535-1544.
131. Gutzmer R, Satzger I, Thoms KM, et al. Sentinel lymph node status is the most important prognostic factor for thick (> or =4 mm) melanomas. *J Dtsch Dermatol Ges*. 2008;6(3):198-203.
132. Scoggins CR, Bowen AL, Martin RC, et al. Prognostic information from sentinel lymph node biopsy in patients with thick melanoma. *Arch Surg*. 2010;145(7):622-627.
133. Dadrass SS, Lange-Asschenfeldt B, Velasco P, et al. Tumor lymphangiogenesis predicts melanoma metastasis to sentinel lymph nodes. *Modern Pathology*. 2005;18(9):1232-1242.
134. Doeden K, Ma Z, Narasimhan B, et al. Lymphatic invasion in cutaneous melanoma is associated with sentinel lymph node metastasis. *Journal of Cutaneous Pathology*. 2009;36(7):772-780.
135. Massi D, Puig S, Franchi A, et al. Tumour lymphangiogenesis is a possible predictor of sentinel lymph node status in cutaneous melanoma: a case-control study. *J Clin Pathol*. 2006;59(2):166-173.
136. Paek S, Griffith K, Johnson T, et al. The impact of factors beyond Breslow depth on predicting sentinel lymph node positivity in melanoma. *Cancer*. 2007;109:100-108.
137. Puleo CA, Messina JL, Riker AI, et al. Sentinel Node Biopsy for Thin Melanomas: Which Patients Should be Considered? *Cancer Control*. 2005;12(4):230-235.
138. Socrier Y, Lauwers-Cances V, Lamant L, et al. Histological regression in primary melanoma: not a predictor of sentinel lymph node metastasis in a cohort of 397 patients. *Br J Dermatol*. 2010;162(4):830-834.

139. Kaur MR, Colloby PS, Martin-Clavijo A, Marsden JR. Melanoma histopathology reporting: are we complying with the National Minimum Dataset? *J Clin Pathol*. 2007;60(10):1121-1123.
140. Leong WL, Ghazarian DM, McCready DR. Previous wide local excision of primary melanoma is not a contraindication for sentinel lymph node biopsy of the trunk and extremity. *Journal of Surgical Oncology*. 2003;82(3):143-146.
141. McCready DR, Ghazarian DM, Hershkop MS, et al. Sentinel lymph-node biopsy after previous wide local excision for melanoma. *Can J Surg*. 2001;44(6):432-434.
142. Alazraki N, Glass E, Castronovo F, et al. Procedure Guideline for Lymphoscintigraphy and the Use of Intraoperative Gamma Probe for Sentinel Lymph Node Localization in Melanoma of Intermediate Thickness 1.0. *Journal of nuclear medicine : official publication, Society of Nuclear Medicine*. 2002;43:1414-1418.
143. Chakera AH, Hesse B, Burak Z, et al. EANM-EORTC general recommendations for sentinel node diagnostics in melanoma. *Eur J Nucl Med Mol Imaging*. 2009;36(10):1713-1742.
144. Cochran AJ, Balda BR, Starz H, et al. The Augsburg consensus. *Cancer*. 2000;89(2):236-241.
145. Vogt H, Schmidt M, Bares R, et al. Procedure guideline for sentinel lymph node diagnosis. *Nuklearmedizin*. 2010;49(4):167-172; quiz N19.
146. Satzger I. Sentinel node biopsy in malignant melanoma. *Onkologe*. 2010;16(12):1140.
147. Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. *Arch Surg*. 1992;127(4):392-399.
148. Even-Sapir E, Lerman H, Lievshitz G, et al. Lymphoscintigraphy for sentinel node mapping using a hybrid SPECT/CT system. *J Nucl Med*. 2003;44(9):1413-1420.
149. Mar M, Miller S, Kim E, Macapinlac H. Evaluation and localization of lymphatic drainage and sentinel lymph nodes in patients with head and neck melanomas by hybrid SPECT/CT lymphoscintigraphic imaging. *Journal of nuclear medicine technology*. 2007;35:10-16; quiz 17.
150. Dengel L, More MJ, Judy P, et al. Intraoperative Imaging Guidance for Sentinel Node Biopsy in Melanoma Using a Mobile Gamma Camera. *Annals of surgery*. 2011;253:774-778.
151. Vidal-Sicart S, Paredes P, Zanón G, et al. Added Value of Intraoperative Real-Time Imaging in Searches for Difficult-to-Locate Sentinel Nodes. *Journal of nuclear medicine : official publication, Society of Nuclear Medicine*. 2010;51:1219-1225.
152. Chakera AH, Lock-Andersen J, Hesse U, et al. One-day or two-day procedure for sentinel node biopsy in melanoma? *Eur J Nucl Med Mol Imaging*. 2009;36(6):928-937.
153. Wendler T, Herrmann K, Schnelzer A, et al. First demonstration of 3-D lymphatic mapping in breast cancer using freehand SPECT. *European journal of nuclear medicine and molecular imaging*. 2010;37:1452-1461.
154. Bostick P, Essner R, Glass E, et al. Comparison of blue dye and probe-assisted intraoperative lymphatic mapping in melanoma to identify sentinel nodes in 100 lymphatic basins. *Arch Surg*. 1999;134(1):43-49.
155. Kretschmer L, Peeters S, Beckmann I, et al. [Intraoperative detection of sentinel lymph nodes in cutaneous malignant melanoma -- blue dye alone versus blue dye plus gamma detection]. *J Dtsch Dermatol Ges*. 2005;3(8):615-622.
156. King TA, Fey JV, Van Zee KJ, et al. A Prospective Analysis of the Effect of Blue-Dye Volume on Sentinel Lymph Node Mapping Success and Incidence of Allergic Reaction in Patients With Breast Cancer. *Ann Surg Oncol*. 2004;11(5):535-541.
157. Lloyd MS, Topping A, Allan R, Powell B. Contraindications to sentinel lymph node biopsy in cutaneous malignant melanoma. *British Journal of Plastic Surgery*. 2004;57(8):725-727.
158. Abrahamsen HN, Hamilton-Dutoit SJ, Larsen J, Steiniche T. Sentinel lymph nodes in malignant melanoma. *Cancer*. 2004;100(8):1683-1691.
159. Cook MG, Green MA, Anderson B, et al. The development of optimal pathological assessment of sentinel lymph nodes for melanoma. *J Pathol*. 2003;200(3):314-319.
160. Gietema H, Vuylsteke R, Jonge I, et al. Sentinel lymph node investigation in melanoma: detailed analysis of the yield from step sectioning and immunohistochemistry. *Journal of clinical pathology*. 2004;57:618-620.
161. Spanknebel K, Coit DG, Bielick SC, et al. Characterization of Micrometastatic Disease in Melanoma Sentinel Lymph Nodes by Enhanced Pathology: Recommendations for Standardizing Pathologic Analysis. *The American Journal of Surgical Pathology*. 2005;29(3):305-317.
162. Mitteldorf C, Bertsch HP, Zapf A, et al. Cutting a sentinel lymph node into slices is the optimal first step for examination of sentinel lymph nodes in melanoma patients. *Mod Pathol*. 2009;22(12):1622-1627.
163. Satzger I, Völker B, Ghazal M, et al. Prognostic significance of histopathological parameters in sentinel nodes of melanoma patients. *Histopathology*. 2007;50:764-772.
164. Starz H, Balda BR, Krämer KU, et al. A micromorphometry-based concept for routine classification of sentinel lymph node metastases and its clinical relevance for patients with melanoma. *Cancer*. 2001;91(11):2110-2121.
165. van Akkooi ACJ, Spatz A, Eggermont AMM, et al. Expert opinion in melanoma: the sentinel node; EORTC Melanoma Group recommendations on practical methodology of the measurement of the microanatomic location of metastases and metastatic tumour burden. *Eur J Cancer*. 2009;45(16):2736-2742.
166. Garbe C, Eigentler T, Bauer J, et al. Histopathological diagnostics of malignant melanoma in accordance with the recent AJCC classification 2009: Review of the literature and recommendations for general practice. *JDDG*. 2011;9:690-699.
167. Meier A, Satzger I, Völker B. Comparison of classification systems in melanoma sentinel lymph nodes—An analysis of 697 patients from a single center. *Cancer*. 2010;116(13):3178-3178.
168. Starz H, Siedlecki K, Balda BR. Sentinel lymphonodectomy and s-classification: a successful strategy for better prediction and improvement of outcome of melanoma. *Ann Surg Oncol*. 2004;11(3 Suppl):162S-8S.
169. Akkooi A, de Wilt J (Johannes), Verhoef K, et al. Clinical relevance of melanoma micrometastases (< 0.1 mm) in sentinel nodes: are these nodes to be considered negative? *Annals of Oncology*. 2006;17(10):1578-1585.
170. Négrier S, Saiag P, Guillot B, et al. Guidelines for clinical practice: Standards, Options and Recommendations 2005 for the management of adult patients exhibiting an M0 cutaneous melanoma, full report. National Federation of Cancer Campaign Centers. French Dermatology Society. Update of the 1995 Consensus Conference and the 1998 Standards, Options, and Recommendations]. *Ann Dermatol Venereol*. 2005;132(12 Pt 2):10S3-10S85.
171. Stojadinovic A, Allen PJ, Clary BM, et al. Value of Frozen-Section Analysis of Sentinel Lymph Nodes for Primary Cutaneous Malignant Melanoma. *Ann Surg*. 2002;235(1):92-98.
172. Blaheta HJ, Ellwanger U, Schitteck B, et al. Examination of regional lymph nodes by sentinel node biopsy and molecular analysis provides new staging facilities in primary cutaneous melanoma. *J Invest Dermatol*. 2000;114(4):637-642.
173. Kuo CT, Hoon DSB, Takeuchi H, et al. Prediction of disease outcome in melanoma patients by molecular analysis of paraffin-embedded sentinel lymph nodes. *J Clin Oncol*. 2003;21(19):3566-3572.
174. Palmieri G, Ascierto P, Cossu A, et al. Detection of Occult Melanoma Cells in Paraffin-Embedded Histologically Negative Sentinel Lymph Nodes Using a Reverse Transcriptase Polymerase Chain Reaction Assay. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2001;19:1437-1443.
175. Ribuffo D, Gradilone A, Vonella M, et al. Prognostic significance of reverse transcriptase-polymerase chain reaction-negative sentinel nodes in malignant melanoma. *Annals of surgical oncology*. 2003;10(4):396-402.
176. Rimoldi D, Lemoine R, Kurt AM, et al. Detection of micrometastases in sentinel lymph nodes from melanoma patients: direct comparison of multimarker molecular and immunopathological methods. *Melanoma Research*. 2003;13(5):511-520.
177. Gutzmer R, Kaspari M, Brodersen JP, et al. Specificity of tyrosinase and HMB45 PCR in the detection of melanoma metastases in sentinel lymph node biopsies. *Histopathology*. 2002;41(6):510-518.
178. Murali R, Desilva C, Thompson JF, Scolyer RA. Non-Sentinel Node Risk Score (N-SNORE): a scoring system for accurately stratifying risk of non-sentinel node positivity in patients with cutaneous melanoma with positive sentinel lymph nodes. *J Clin Oncol*. 2010;28(29):4441-4449.
179. Satzger I, Völker B, Meier A, et al. Criteria in Sentinel Lymph Nodes of Melanoma Patients that Predict Involvement of Nonsentinel Lymph Nodes. *Annals of surgical oncology*. 2008;15:1723-1732.
180. Scolyer RA, Li LXL, McCarthy SW, et al. Micromorphometric features of positive sentinel lymph nodes predict involvement of nonsentinel nodes in patients with melanoma. *Am J Clin Pathol*. 2004;122(4):532-539.
181. Dewar D, Newell B, Green M, Topping A, Powell B, Cook M. The Microanatomic Location of Metastatic Melanoma in Sentinel Lymph Nodes Predicts Nonsentinel Lymph Node Involvement. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2004;22:3345-3349.

182. Murali R, Cochran AJ, Cook MG, et al. Inter-observer reproducibility of histologic parameters of melanoma deposits in sentinel lymph nodes: implications for management of patients with melanoma. *Cancer*. 2009;115(21):5026-5037.
183. Balch CM, Gershenwald JE, Soong S jaw, et al. Multivariate Analysis of Prognostic Factors Among 2,313 Patients With Stage III Melanoma: Comparison of Nodal Micrometastases Versus Macrometastases. *J Clin Oncol*. 2010;28(14):2452-2459.
184. Debarbieux S, Duru G, Dalle S, et al. Sentinel lymph node biopsy in melanoma: a micromorphometric study relating to prognosis and completion lymph node dissection. *British Journal of Dermatology*. 2007;157(1):58-67.
185. Riber-Hansen R, Nyengaard JR, Hamilton-Dutoit SJ, et al. Metastatic melanoma volume in sentinel nodes: objective stereology-based measurement predicts disease recurrence and survival. *Histopathology*. 2009;54(7):796-803.
186. Ploeg A, van Akkooi A, Rutkowski P, et al. Prognosis in Patients With Sentinel Node-Positive Melanoma Is Accurately Defined by the Combined Rotterdam Tumor Load and Dewar Topography Criteria. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2011;29:2206-2214.
187. Frankel T, Griffith K, Lowe L, et al. Do Micromorphometric Features of Metastatic Deposits Within Sentinel Nodes Predict Nonsentinel Lymph Node Involvement in Melanoma? *Annals of surgical oncology*. 2008;15:2403-2411.
188. Satzger I, Völker B, Meier A, et al. Prognostic Significance of Isolated HMB45 or Melan A Positive Cells in Melanoma Sentinel Lymph Nodes. *The American Journal of Surgical Pathology*. 2007;31(8):1175-1180.
189. Ploeg IMC van der, Kroon BBR, Antonini N, et al. Is completion lymph node dissection needed in case of minimal melanoma metastasis in the sentinel node? *Ann Surg*. 2009;249(6):1003-1007.
190. Herman K, Wysocki WM, Skotnicki P, et al. Stage III thick (>4.0 mm) lower extremity melanoma: is timing of lymph node involvement a prognostic factor. *World J Surg*. 2009;33(3):469-474.
191. Roses DF, Karp NS, Oratz R, et al. Survival with regional and distant metastases from cutaneous malignant melanoma. *Surg Gynecol Obstet*. 1991;172(4):262-268.
192. Weide B, Eigentler TK, Pflugfelder A, et al. Survival after intratumoral interleukin-2 treatment of 72 melanoma patients and response upon the first chemotherapy during follow-up. *Cancer Immunology, Immunotherapy*. 2011;60(4):487-493.
193. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. *J Clin Oncol*. 2001;19(16):3635-3648.
194. Kim CJ, Reintgen DS, Balch CM, AJCC Melanoma Staging Committee. The new melanoma staging system. *Cancer Control*. 2002;9(1):9-15.
195. Bleicher J, Swords DS, Mali ME, et al. Recurrence patterns in patients with Stage II melanoma: The evolving role of routine imaging for surveillance. *Journal of Surgical Oncology*. 2020;122(8):1770-1777.
196. Eggermont AMM, Blank CU, Mandala M, et al. Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial. *J Clin Oncol*. 2020;38(33):3925-3936.
197. Kanaki T, Stang A, Gutzmer R, et al. Impact of American Joint Committee on Cancer 8th edition classification on staging and survival of patients with melanoma. *Eur J Cancer*. 2019;119:18-29.
198. Garbe C, Keim U, Suci S, et al. Prognosis of Patients With Stage III Melanoma According to American Joint Committee on Cancer Version 8: A Reassessment on the Basis of 3 Independent Stage III Melanoma Cohorts. *J Clin Oncol*. 2020;38(22):2543-2551.
199. Tsao H, Feldman M, Fullerton JE, et al. Early detection of asymptomatic pulmonary melanoma metastases by routine chest radiographs is not associated with improved survival. *Arch Dermatol*. 2004;140(1):67-70.
200. Garbe C, Amaral T, Peris K, et al. European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022. *European Journal of Cancer*. 2022;170:236-255.
201. Pfannenberger C, Aschoff P, Schanz S, et al. Prospective comparison of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced malignant melanoma. *European journal of cancer (Oxford, England : 1990)*. 2007;43:557-564.
202. Müller-Horvat C, Radny P, Eigentler TK, et al. Prospective comparison of the impact on treatment decisions of whole-body magnetic resonance imaging and computed tomography in patients with metastatic malignant melanoma. *Eur J Cancer*. 2006;42(3):342-350.
203. Fogarty GB, Tartagui C. The utility of magnetic resonance imaging in the detection of brain metastases in the staging of cutaneous melanoma. *Clin Oncol (R Coll Radiol)*. 2006;18(4):360-362.
204. Schlamann M, Goericke S, Forsting M, et al. Cerebral MRI in neurological asymptomatic patients with malignant melanoma; Zerebrales MRT bei neurologisch asymptomatischen Patienten mit malignem Melanom. *RoeFo - Fortschritte auf dem Gebiete der Roentgenstrahlen und der Neuen Bildgebenden Verfahren*. 2008;180.
205. Kruijff S, Bastiaannet E, Muller Kobold AC, et al. S-100B Concentrations Predict Disease-Free Survival in Stage III Melanoma Patients. *Ann Surg Oncol*. 2009;16(12):3455-3462.
206. Schultz ES, Diepgen TL, Von Den Driesch P. Clinical and prognostic relevance of serum S-100 beta protein in malignant melanoma. *Br J Dermatol*. 1998;138(3):426-430.
207. Brouard M, Quillien V, Ollivier I, et al. Serum S100B protein and stage of cutaneous melanoma: a prospective study. *Ann Dermatol Venereol*. 2000;127(1):56-59.
208. Kaskel P, Berking C, Sander S, et al. S-100 protein in peripheral blood: A marker for melanoma metastases: A prospective 2-center study of 570 patients with melanoma. *Journal of the American Academy of Dermatology*. 1999;41(6):962-969.
209. Krähn G, Kaskel P, Sander S, et al. S100 beta is a more reliable tumor marker in peripheral blood for patients with newly occurred melanoma metastases compared with MIA, albumin and lactate-dehydrogenase. *Anticancer Res*. 2001;21(2B):1311-1316.
210. Nowecki ZI, Rutkowski P, Kulik J, et al. Molecular and biochemical testing in stage III melanoma: multimarker reverse transcriptase-polymerase chain reaction assay of lymph fluid after lymph node dissection and preoperative serum lactate dehydrogenase level. *British Journal of Dermatology*. 2008;159(3):597-605.
211. Garnier JP, Letellier S, Cassinat B, et al. Clinical value of combined determination of plasma L-DOPA/tyrosine ratio, S100B, MIA and LDH in melanoma. *Eur J Cancer*. 2007;43(4):816-821.
212. Lens MB, Dawes M, Goodacre T, Newton-Bishop JA. Elective lymph node dissection in patients with melanoma: systematic review and meta-analysis of randomized controlled trials. *Arch Surg*. 2002;137(4):458-461.
213. O'Brien CJ, Gianoutsos MP, Morgan MJ. Neck dissection for cutaneous malignant melanoma. *World J Surg*. 1992;16(2):222-226.
214. Morton DL, Wanek L, Nizze JA, et al. Improved long-term survival after lymphadenectomy of melanoma metastatic to regional nodes. Analysis of prognostic factors in 1134 patients from the John Wayne Cancer Clinic. *Ann Surg*. 1991;214(4):491-499; discussion 499-501.
215. Hafner J, Schmid MH, Kempf W, et al. Baseline staging in cutaneous malignant melanoma. *British Journal of Dermatology*. 2004;150(4):677-686.
216. Hofmann U, Szedlak M, Rittgen W, et al. Primary staging and follow-up in melanoma patients – monocenter evaluation of methods, costs and patient survival. *Br J Cancer*. 2002;87(2):151-157.
217. Fink AM, Holle-Robatsch S, Herzog N, et al. Positron emission tomography is not useful in detecting metastasis in the sentinel lymph node in patients with primary malignant melanoma stage I and II. *Melanoma Res*. 2004;14(2):141-145.
218. Starritt EC, Uren RF, Scolyer RA, et al. Ultrasound Examination of Sentinel Nodes in the Initial Assessment of Patients With Primary Cutaneous Melanoma. *Ann Surg Oncol*. 2005;12(1):18-23.
219. van der Ploeg APT, Haydu LE, Spillane AJ, et al. Outcome following sentinel node biopsy plus wide local excision versus wide local excision only for primary cutaneous melanoma: analysis of 5840 patients treated at a single institution. *Ann Surg*. 2014;260(1):149-157.
220. Nagaraja V, Eslick GD. Is complete lymph node dissection after a positive sentinel lymph node biopsy for cutaneous melanoma always necessary? A meta-analysis. *European Journal of Surgical Oncology (EJSO)*. 2013;39(7):669-680.
221. Satzger I, Meier A, Alter M, et al. Which Parameters to Choose for Prediction of Non-Sentinel Lymph Node Positivity in Melanoma? *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2011;29:e315; author reply e316-7.
222. Egger ME, Bower MR, Czystyszczon IA, et al. Comparison of sentinel lymph node micrometastatic tumor burden measurements in melanoma. *J Am Coll Surg*. 2014;218(4):519-528.
223. Murali R, Desilva C, Thompson JF, Scolyer RA. Factors Predicting Recurrence and Survival in Sentinel Lymph Node-Positive Melanoma Patients. *Annals of Surgery*. 2011;253(6):1155-1164.

224. Satzger I, Meier A, Zapf A, et al. Is there a therapeutic benefit of complete lymph node dissection in melanoma patients with low tumor burden in the sentinel node? *Melanoma Research*. 2014;24(5):454-461.
225. van der Ploeg APT, van Akkooi ACJ, Rutkowski P, et al. Prognosis in patients with sentinel node-positive melanoma without immediate completion lymph node dissection. *BJS (British Journal of Surgery)*. 2012;99(10):1396-1405.
226. Bamboat Z, Konstantinidis I, Kuk D, et al. Observation After a Positive Sentinel Lymph Node Biopsy in Patients with Melanoma. *Annals of surgical oncology*. 2014;21.
227. Jakub JW, Reintgen DS, Shivers S, Pendas S. Regional Node Dissection for Melanoma: Techniques and Indication. *Surgical Oncology Clinics of North America*. 2007;16(1):247-261.
228. Mack LA, McKinnon JG. Controversies in the management of metastatic melanoma to regional lymphatic basins. *J Surg Oncol*. 2004;86(4):189-199.
229. Easson AM, Rotstein LE, McCready DR. Lymph node assessment in melanoma. *J Surg Oncol*. 2009;99(4):176-185.
230. Spillane AJ, Cheung BLH, Stretch JR, et al. Proposed Quality Standards for Regional Lymph Node Dissections in Patients With Melanoma. *Annals of Surgery*. 2009;249(3):473-480.
231. Neuss H, Reetz C, Raue W, et al. Postoperative surgical complications after radical axillary lymph node dissection in melanoma disease result in increased pain. *Int Surg*. 2010;95(2):166-171.
232. Creagan ET, Cupps RE, Ivins JC, et al. Adjuvant radiation therapy for regional nodal metastases from malignant melanoma. A randomized, prospective study. *Cancer*. 1978;42(5):2206-2210.
233. Henderson MA, Burmeister BH, Ainslie J, et al. Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial. *Lancet Oncol*. 2015;16(9):1049-1060.
234. Agrawal S, Kane JM, Guadagnolo BA, Kraybill WG, Ballo MT. The benefits of adjuvant radiation therapy after therapeutic lymphadenectomy for clinically advanced, high-risk, lymph node-metastatic melanoma. *Cancer*. 2009;115(24):5836-5844.
235. Hamming-Vrieze O, Balm AJM, Heemsbergen WD, Huysduynen TH van, Rasch CRN. Regional control of melanoma neck node metastasis after selective neck dissection with or without adjuvant radiotherapy. *Arch Otolaryngol Head Neck Surg*. 2009;135(8):795-800.
236. O'Brien CJ, Petersen-Schaefer K, Stevens GN, et al. Adjuvant radiotherapy following neck dissection and parotidectomy for metastatic malignant melanoma. *Head & Neck*. 1997;19(7):589-594.
237. Strojan P, Jancar B, Cemazar M, et al. Melanoma metastases to the neck nodes: role of adjuvant irradiation. *Int J Radiat Oncol Biol Phys*. 2010;77(4):1039-1045.
238. Barbour S, Mark Smithers B, Allan C, et al. Patterns of Recurrence in Patients with Stage IIIB/C Cutaneous Melanoma of the Head and Neck Following Surgery With and Without Adjuvant Radiation Therapy: Is Isolated Regional Recurrence Salvageable? *Ann Surg Oncol*. 2015;22(12):4052-4059.
239. Danish HH, Patel KR, Switchenko JM, et al. The influence of postoperative lymph node radiation therapy on overall survival of patients with stage III melanoma, a National Cancer Database analysis. *Melanoma Res*. 2016;26(6):595-603.
240. Mendenhall WM, Shaw C, Amdur RJ, et al. Surgery and adjuvant radiotherapy for cutaneous melanoma considered high-risk for local-regional recurrence. *Am J Otolaryngol*. 2013;34(4):320-322.
241. Pinkham MB, Foote MC, Burmeister E, et al. Stage III Melanoma in the Axilla: Patterns of Regional Recurrence After Surgery With and Without Adjuvant Radiation Therapy. *International Journal of Radiation Oncology*Biophysics*. 2013;86(4):702-708.
242. Moncrieff M, Martin R, O'Brien C, et al. Adjuvant Postoperative Radiotherapy to the Cervical Lymph Nodes in Cutaneous Melanoma: Is There Any Benefit for High-Risk Patients? *Ann Surg Oncol*. 2008;15:3022-3027.
243. Shen P, Wanek LA, Morton DL. Is adjuvant radiotherapy necessary after positive lymph node dissection in head and neck melanomas? *Ann Surg Oncol*. 2000;7(8):554-559; discussion 560-561.
244. Fuhrmann D, Lippold A, Borrosch F, et al. Should adjuvant radiotherapy be recommended following resection of regional lymph node metastases of malignant melanomas? *Br J Dermatol*. 2001;144(1):66-70.
245. Horvat A, Jancar B, Blas M, et al. Adjuvant Radiotherapy for Palpable Melanoma Metastases to the Groin: When to Irradiate? *International journal of radiation oncology, biology, physics*. 2011;83:310-316.
246. Bibault JE, Dewas S, Mirabel X, et al. Adjuvant radiation therapy in metastatic lymph nodes from melanoma. *Radiat Oncol*. 2011;6:12.
247. Henderson M, Thompson J, Diiulio J, et al. Adjuvant radiotherapy and regional lymph node field control in melanoma patients after lymphadenectomy: Results of an intergroup randomized trial (ANZMTG 01.02/TROG 02.01). *Journal of Clinical Oncology*. 2009;27:LBA9084-LBA9084.
248. Suci S, Eggermont AMM, Lorigan P, et al. Relapse-Free Survival as a Surrogate for Overall Survival in the Evaluation of Stage II-III Melanoma Adjuvant Therapy. *J Natl Cancer Inst*. 2018;110(1).
249. Eggermont AMM, Blank CU, Mandala M, et al. Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. *N Engl J Med*. 2018;378(19):1789-1801.
250. Weber J, Mandala M, Del Vecchio M, et al. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. *N Engl J Med*. 2017;377(19):1824-1835.
251. Ascierto PA, Del Vecchio M, Mandalá M, et al. Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. *Lancet Oncol*. 2020;21(11):1465-1477.
252. Eggermont AMM, Blank CU, Mandalá M, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. *Lancet Oncol*. 2021;22(5):643-654.
253. Eggermont AMM, Chiarion-Sileni V, Grob JJ, et al. Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial. *European journal of cancer & clinical oncology*. 2019;119:1-10.
254. Long GV, Hauschild A, Santinami M, et al. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. *N Engl J Med*. 2017;377(19):1813-1823.
255. Maio M, Lewis K, Demidov L, et al. Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. *The Lancet Oncology*. 2018;19(4):510-520.
256. Dummer R, Hauschild A, Santinami M, et al. Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. *N Engl J Med*. 2020;383(12):1139-1148.
257. Atkinson V, Robert C, Grob JJ, et al. Improved pyrexia-related outcomes associated with an adapted pyrexia adverse event management algorithm in patients treated with adjuvant dabrafenib plus trametinib: Primary results of COMBI-APlus. *European Journal of Cancer*. 2022;163:79-87.
258. Michielin O, van Akkooi A, Lorigan P, et al. ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee. *Annals of Oncology*. 2020;31(11):1449-1461.
259. Seth R, Messersmith H, Kaur V, et al. Systemic Therapy for Melanoma: ASCO Guideline - PubMed. Published 2020. Accessed August 17, 2022. <https://pubmed.ncbi.nlm.nih.gov/ezproxy.muni.cz/32228358/>
260. Tarhini AA, Lee SJ, Hodi FS, et al. Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609. *J Clin Oncol*. 2020;38(6):567-575.
261. Dummer R, Hauschild A, Santinami M, et al. Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. *N Engl J Med*. 2020;383(12):1139-1148.
262. Dinnes J, Ferrante di Ruffano L, Takwoingi Y, et al. Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma. *Cochrane Database Syst Rev*. 2019;7:CD012806.
263. Davila D, Antoniou A, Chaudhry MA. Evaluation of osseous metastasis in bone scintigraphy. *Semin Nucl Med*. 2015;45(1):3-15.
264. Paschen A, Sucker A, Hill B, et al. Differential Clinical Significance of Individual NKG2D Ligands in Melanoma: Soluble ULBP2 as an Indicator of Poor Prognosis Superior to S100B. *Clinical Cancer Research*. 2009;15(16):5208-5215.
265. Andrés R, Mayordomo JI, Zaballos P, et al. Prognostic value of serum S-100B in malignant melanoma. *Tumori*. 2004;90(6):607-610.
266. Brouard M, Quillien V, Ollivier I, Lesimple T, Adamski H, Chevrant-Breton J. Serum S100B protein and cutaneous malignant melanoma stage: A prospective study. *Annales de dermatologie et de vénéréologie*. 2000;127:56-59.

267. Agarwala S, Keilholz U, Gilles E, et al. LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951). *European Journal of Cancer*. 2009;45(10):1807-1814.
268. Deichmann M, Benner A, Bock M, et al. S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma. *J Clin Oncol*. 1999;17(6):1891-1896.
269. Schlagenhauff B, Stroebe W, Ellwanger U, et al. Metastatic melanoma of unknown primary origin shows prognostic similarities to regional metastatic melanoma: recommendations for initial staging examinations. *Cancer*. 1997;80(1):60-65.
270. Lowes M, Bishop A, Crotty K, Barnetson R, Halliday G. T Helper 1 Cytokine mRNA Is Increased in Spontaneously Regressing Primary Melanomas. *The Journal of investigative dermatology*. 1997;108:914-919.
271. Prens SP, van der Ploeg APT, van Akkooi ACJ, et al. Outcome After Therapeutic Lymph Node Dissection in Patients with Unknown Primary Melanoma Site. *Ann Surg Oncol*. 2011;18(13):3586-3592.
272. Tefany FJ, Barnetson RS, Halliday GM, McCarthy SW, McCarthy WH. Immunocytochemical Analysis of the Cellular Infiltrate in Primary Regressing and Non-Regressing Malignant Melanoma. *Journal of Investigative Dermatology*. 1991;97(2):197-202.
273. Lee C, Faries M, Wanek L, Morton D. Improved Survival After Lymphadenectomy for Nodal Metastasis From an Unknown Primary Melanoma. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2008;26:535-541.
274. Vijuk G, Coates AS. Survival of patients with visceral metastatic melanoma from an occult primary lesion: A retrospective matched cohort study. *Annals of Oncology*. 1998;9(4):419-422.
275. Tos T, Klyver H, Drzewiecki KT. Extensive screening for primary tumor is redundant in melanoma of unknown primary. *Journal of Surgical Oncology*. 2011;104(7):724-727.
276. Garbe C, Eigentler TK, Keilholz U, Hauschild A, Kirkwood JM. Systematic review of medical treatment in melanoma: current status and future prospects. *Oncologist*. 2011;16(1):5-24.
277. Goel VK, Lazar AJF, Warneke CL, et al. Examination of Mutations in BRAF, NRAS, and PTEN in Primary Cutaneous Melanoma. *Journal of Investigative Dermatology*. 2006;126(1):154-160.
278. Ascierto PA, Schadendorf D, Berking C, et al. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. *Lancet Oncol*. 2013;14(3):249-256.
279. Carvajal RD, Antonescu CR, Wolchok JD, et al. KIT as a Therapeutic Target in Metastatic Melanoma. *JAMA*. 2011;305(22):2327-2334.
280. Guo J, Si L, Kong Y, et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. *J Clin Oncol*. 2011;29(21):2904-2909.
281. Leo F, Cagini L, Rocmans P, et al. Lung metastases from melanoma: when is surgical treatment warranted? *Br J Cancer*. 2000;83(5):569-572.
282. Delaunay MM, Amici JM, Avril MF, et al. [Surgery of pulmonary metastasis from malignant melanoma. Results and criteria of surgical excision]. *Ann Dermatol Venereol*. 1991;118(4):287-295.
283. Mathisen DJ, Flye MW, Peabody J. The Role of Thoracotomy in the Management of Pulmonary Metastases from Malignant Melanoma. *The Annals of Thoracic Surgery*. 1979;27(4):295-299.
284. Petersen RP, Hanish SI, Haney JC, et al. Improved survival with pulmonary metastasectomy: An analysis of 1720 patients with pulmonary metastatic melanoma. *The Journal of Thoracic and Cardiovascular Surgery*. 2007;133(1):104-110.e2.
285. Brand CU, Ellwanger U, Stroebe W, et al. Prolonged survival of 2 years or longer for patients with disseminated melanoma. An analysis of related prognostic factors. *Cancer*. 1997;79(12):2345-2353.
286. Sanki A, Scolyer RA, Thompson JF. Surgery for melanoma metastases of the gastrointestinal tract: Indications and results. *European Journal of Surgical Oncology (EJSO)*. 2009;35(3):313-319.
287. Harpole DH, Johnson CM, Wolfe WG, et al. Analysis of 945 cases of pulmonary metastatic melanoma. *J Thorac Cardiovasc Surg*. 1992;103(4):743-748; discussion 748-750.
288. Andrews S, Robinson L, Cantor A, DeConti RC. Survival after surgical resection of isolated pulmonary metastases from malignant melanoma. *Cancer Control*. 2006;13(3):218-223.
289. Neuman HB, Patel A, Hanlon C, et al. Stage-IV Melanoma and Pulmonary Metastases: Factors Predictive of Survival. *Ann Surg Oncol*. 2007;14(10):2847-2853.
290. Albert J, Fechner M, Fiedler E, et al. Algorithm for detection of small-bowel metastasis in malignant melanoma of the skin. *Endoscopy*. 2011;43:490-498.
291. Chua TC, Saxena A, Morris DL. Surgical metastasectomy in AJCC stage IV M1c melanoma patients with gastrointestinal and liver metastases. *Ann Acad Med Singap*. 2010;39(8):634-639.
292. Pawlik T, Zorzi D, Abdalla E, et al. Hepatic Resection for Metastatic Melanoma: Distinct Patterns of Recurrence and Prognosis for Ocular Versus Cutaneous Disease. *Annals of surgical oncology*. 2006;13:712-720.
293. Branum GD, Epstein RE, Leight GS, Seigler HF. The role of resection in the management of melanoma metastatic to the adrenal gland. *Surgery*. 1991;109(2):127-131.
294. Sosman JA, Moon J, Tuthill RJ, et al. A Phase II Trial of Complete Resection for Stage IV Melanoma: Results of Southwest Oncology Group (SWOG) Clinical Trial S9430. *Cancer*. 2011;117(20):4740-4706.
295. Galata C, Wimmer E, Kasper B, et al. Multidisciplinary Tumor Board Recommendations for Oligometastatic Malignancies: A Prospective Single-Center Analysis. *ORT*. 2019;42(3):87-94.
296. Ch'ng S, Uyulmaz S, Carlino MS, et al. Re-defining the role of surgery in the management of patients with oligometastatic stage IV melanoma in the era of effective systemic therapies. *Eur J Cancer*. 2021;153:8-15.
297. Nelson DW, Fischer TD, Graff-Baker AN, et al. Impact of Effective Systemic Therapy on Metastasectomy in Stage IV Melanoma: A Matched-Pair Analysis. *Ann Surg Oncol*. 2019;26(13):4610-4618.
298. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. *Nature*. 2002;417(6892):949-954.
299. Robert C, Grob JJ, Stryakovsky D, et al. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. *NEW ENGL J MED*. 2019;381(7):626-636.
300. Long GV, Stryakovsky D, Gogas H, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. *Lancet*. 2015;386(9992):444-451.
301. Long GV, Flaherty KT, Stryakovsky D, et al. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. *Annals of oncology : official journal of the European Society for Medical Oncology*. 2017;28(7):1631-1639.
302. Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. *N Engl J Med*. 2015;372(1):30-39.
303. Larkin J, Ascierto PA, Dréno B, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. *N Engl J Med*. 2014;371(20):1867-1876.
304. Ascierto PA, Dréno B, Larkin J, et al. 5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation-Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study. *Clinical Cancer Research*. 2021;27(19):5225-5235.
305. Schadendorf D, Dummer R, Flaherty KT, et al. COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanoma. *Eur J Cancer*. 2024 Apr 24;204:114073.
306. Mai R, Zhou S, Zhong W, et al. Therapeutic efficacy of combined BRAF and MEK inhibition in metastatic melanoma: A comprehensive network meta-analysis of randomized controlled trials. *Oncotarget*. 2015;6.
307. Davies MA, Saiag P, Robert C, et al. Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. *Lancet Oncol*. 2017;18(7):863-873.
308. Tawbi HA, Forsyth PA, Hodi FS, et al. Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study. *Lancet Oncol*. 2021;22(12):1692-1704.
309. Marquez-Rodas I, Arance A, Berciano-Guerrero M, et al. 1038MO Intracranial activity of encorafenib and binimetinib followed by radiotherapy in patients with BRAF mutated melanoma and brain metastasis: Preliminary results of the GEM1802/EBRAIN-MEL phase II clinical trial. *Annals of Oncology*. 2021;32:S870.
310. Long GV, Atkinson V, Lo S, et al. Five-year overall survival from the anti-PD1 brain collaboration (ABC Study): Randomized phase 2 study of nivolumab (nivo) or nivo+ipilimumab (ipi) in patients (pts) with melanoma brain metastases (mets). *JCO*. 2021;39(15_suppl):9508-9508.
311. Ascierto PA, Melero I, Bhatia S, et al. Initial efficacy of anti-lymphocyte activation gene-3 (anti-LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti-PD-1/PD-L1 therapy. *JCO*. 2017;35(15_suppl):9520-9520.
312. Arance A, de la Cruz-Merino L, Petrella TM, et al. Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death

- Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination. *J Clin Oncol*. Published online July 22, 2022:JCO2200221.
313. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. *N Engl J Med*. 2010;363(8):711-723.
 314. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. *N Engl J Med*. 2011;364(26):2517-2526.
 315. Maio M, Grob JJ, Aamdal S, et al. Five-year survival rates for treatment-naïve patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. *J Clin Oncol*. 2015;33(10):1191-1196.
 316. Robert C, Schadendorf D, Messina M, Hodi FS, O'Day S, for the MDX010-20 investigators. Efficacy and Safety of Retreatment with Ipilimumab in Patients with Pretreated Advanced Melanoma Who Progressed after Initially Achieving Disease Control. *Clinical Cancer Research*. 2013;19(8):2232-2239.
 317. Schadendorf D, Hodi FS, Robert C, et al. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. *J Clin Oncol*. 2015;33(17):1889-1894.
 318. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. *N Engl J Med*. 2015;372(4):320-330.
 319. Robert C, Long GV, Brady B, et al. Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma. *J Clin Oncol*. 2020;38(33):3937-3946.
 320. Robert C, Schachter J, Long GV, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. *N Engl J Med*. 2015;372(26):2521-2532.
 321. Robert C, Ribas A, Schachter J, et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. *The Lancet Oncology*. 2019;20(9):1239-1251.
 322. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. *N Engl J Med*. 2015;373(1):23-34.
 323. Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. *J Clin Oncol*. 2022;40(2):127-137.
 324. Maio M, Grob JJ, Aamdal S, et al. Five-year survival rates for treatment-naïve patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. *J Clin Oncol*. 2015;33(10):1191-1196.
 325. Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. *J Clin Oncol*. 2022;40(2):127-137.
 326. Hamid O, Robert C, Daud A, et al. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. *Ann Oncol*. 2019;30(4):582-588.
 327. Robert C, Ribas A, Schachter J, et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. *The Lancet Oncology*. 2019;20(9):1239-1251.
 328. Tawbi HA, Forsyth PA, Hodi FS, et al. Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study. *Lancet Oncol*. 2021;22(12):1692-1704.
 329. Robert C, Grob JJ, Strydomskiy D, et al. Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. *New England Journal of Medicine*. 2019;381(7):626-636.
 330. Dummer R, Flaherty KT, Robert C, et al. COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600-Mutant Melanoma. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. Published online July 21, 2022.
 331. Carvajal RD, Spencer SA, Lydiatt W. Mucosal melanoma: a clinically and biologically unique disease entity. *J Natl Compr Canc Netw*. 2012;10(3):345-356.
 332. Gru AA, Becker N, Dehner LP, Pfeifer JD. Mucosal melanoma: correlation of clinicopathologic, prognostic, and molecular features. *Melanoma Research*. 2014;24(4):360-370.
 333. Casiraghi O, Lefevre M. Undifferentiated malignant round cell tumors of the sinonasal tract and nasopharynx. *Annales de pathologie*. 2009;29:296-312.
 334. Gondak Ro, da Silva-Jorge R, Jorge J, Lopes Ma, Vargas Pa. Oral pigmented lesions: Clinicopathologic features and review of the literature. *Med Oral*. Published online 2012:e919-e924.
 335. Kerr EH, Hameed O, Lewis JS, et al. Head and neck mucosal malignant melanoma: Clinicopathologic correlation with contemporary review of prognostic indicators. *International Journal of Surgical Pathology*. 2012;20(1):37-46.
 336. Song H, Wu Y, Ren G, et al. Prognostic factors of oral mucosal melanoma: histopathological analysis in a retrospective cohort of 82 cases. *Histopathology*. 2015;67(4):548-556.
 337. Thompson LDR, Wieneke JA, Miettinen M. Sinonasal Tract and Nasopharyngeal Melanomas: A Clinicopathologic Study of 115 Cases With a Proposed Staging System. *The American Journal of Surgical Pathology*. 2003;27(5):594-611.
 338. Chung AF, Woodruff JM, Lewis JL. Malignant melanoma of the vulva: A report of 44 cases. *Obstet Gynecol*. 1975;45(6):638-646.
 339. Podratz KC, Gaffey TA, Symmonds RE, et al. Melanoma of the vulva: An update. *Gynecologic Oncology*. 1983;16(2):153-168.
 340. Zámbo K, Szabó Z, Schmidt E, et al. Is the clinical staging system a good choice in the staging of vulvar malignancies? *Eur J Nucl Med Mol Imaging*. 2007;34(11):1878-1879.
 341. Tcheung WJ, Selim MA, Herndon JE, et al. Clinicopathologic study of 85 cases of melanoma of the female genitalia. *J Am Acad Dermatol*. 2012;67(4):598-605.
 342. Heinzelmann-Schwarz VA, Nixdorf S, Valadan M, et al. A clinicopathological review of 33 patients with vulvar melanoma identifies c-KIT as a prognostic marker. *Int J Mol Med*. 2014;33(4):784-794.
 343. Buchanan DJ, Schlaerth J, Kurosaki T. Primary vaginal melanoma: thirteen-year disease-free survival after wide local excision and review of recent literature. *Am J Obstet Gynecol*. 1998;178(6):1177-1184.
 344. Petru E, Nagele F, Czerwenka K, et al. Primary malignant melanoma of the vagina: long-term remission following radiation therapy. *Gynecol Oncol*. 1998;70(1):23-26.
 345. Leitao MM, Cheng X, Hamilton AL, et al. Gynecologic Cancer InterGroup (GCIg) consensus review for vulvovaginal melanomas. *Int J Gynecol Cancer*. 2014;24(9 Suppl 3):S117-122.
 346. Tacastacas JD, Bray J, Cohen YK, et al. Update on primary mucosal melanoma. *J Am Acad Dermatol*. 2014;71(2):366-375.
 347. Amin MB, Edge SB, Greene FL, et al. *AJCC Cancer Staging Manual*.; 2018. Accessed August 17, 2022. <https://link.springer.com/book/9783319406176>
 348. Samstein RM, Carvajal RD, Postow MA, et al. Localized sinonasal mucosal melanoma: Outcomes and associations with stage, radiotherapy, and positron emission tomography response. *Head & Neck*. 2016;38(9):1310-1317.
 349. Frakes JM, Strom TJ, Naghavi AO, et al. Outcomes of mucosal melanoma of the head and neck. *J Med Imaging Radiat Oncol*. 2016;60(2):268-273.
 350. Sun CZ, Chen YF, Jiang YE, Hu ZD, Yang AK, Song M. Treatment and prognosis of oral mucosal melanoma. *Oral Oncology*. 2012;48(7):647-652.
 351. Luna-Ortiz K, Aguilar-Romero M, Villavicencio-Valencia V, et al. Comparative study between two different staging systems (AJCC TNM VS BALLANTYNE'S) for mucosal melanomas of the Head & Neck. *Med Oral Patol Oral Cir Bucal*. 2016;21(4):e425-30.
 352. Pfister DG, Ang KK, Brizel DM, et al. Mucosal melanoma of the head and neck. *J Natl Compr Canc Netw*. 2012;10(3):320-338.
 353. Moreno MA, Roberts DB, Kupferman ME, et al. Mucosal melanoma of the nose and paranasal sinuses, a contemporary experience from the M. D. Anderson Cancer Center. *Cancer*. 2010;116(9):2215-2223.
 354. López F, Rodrigo JP, Cardesa A, et al. Update on primary head and neck mucosal melanoma. *Head Neck*. 2016;38(1):147-155.
 355. Houette A, Gilain L, Mulliez A, Mom T, Saroul N. Prognostic value of two tumour staging classifications in patients with sinonasal mucosal melanoma. *European annals of otorhinolaryngology, head and neck diseases*. 2016;133.
 356. Wechter ME, Gruber SB, Haefner HK, et al. Vulvar melanoma: a report of 20 cases and review of the literature. *Journal of the American Academy of Dermatology*. 2004;50(4):554-562.
 357. Chae WY, Lee JL, Cho DH, et al. Preliminary Suggestion about Staging of Anorectal Malignant Melanoma May Be Used to Predict Prognosis. *Cancer Res Treat*. 2016;48(1):240-249.
 358. Lutzky J, Bauer J, Bastian BC. Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation. *Pigment Cell & Melanoma Research*. 2008;21(4):492-493.

359. Hodi FS, Friedlander P, Corless CL, et al. Major response to imatinib mesylate in KIT-mutated melanoma. *J Clin Oncol*. 2008;26(12):2046-2051.
360. Handolias D, Hamilton AL, Salemi R, et al. Clinical responses observed with imatinib or sora-fenib in melanoma patients expressing mutations in KIT. *Br J Cancer*. 2010;102(8):1219-1223.
361. Hodi FS, Corless CL, Giobbie-Hurder A, et al. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. *J Clin Oncol*. 2013;31(26):3182-3190.
362. Cullinane C, Natoli A, Hui Y, et al. Preclinical Evaluation of Nilotinib Efficacy in an Imatinib-Resistant KIT-Driven Tumor Model. *Molecular Cancer Therapeutics*. 2010;9(5):1461-1468.
363. Carvajal RD, Lawrence DP, Weber JS, et al. Phase II study of nilotinib in melanoma harbo-ring KIT alterations following progression to prior KIT inhibition. *Clinical Cancer Research*. 2015;21(10):2289-2296.
364. Lee SJ, Kim TM, Kim YJ, et al. Phase II Trial of Nilotinib in Patients With Metastatic Malignant Melanoma Harboring KIT Gene Aberration: A Multicenter Trial of Korean Cancer Study Group (UN10-06). *Oncologist*. 2015;20(11):1312-1319.
365. Gore MR, Zanation AM. Survival in Sinonasal Melanoma: A Meta-analysis. *J Neurol Surg B Skull Base*. 2012;73(3):157-162.
366. Ciarrocchi A, Pietroletti R, Carlei F, Amicucci G. Extensive surgery and lymphadenectomy do not improve survival in primary melanoma of the anorectum: results from analysis of a large database (SEER). *Colorectal Disease*. 2017;19(2):158-164.
367. Medina JE, Ferlito A, Brandwein MS, et al. Current management of cutaneous malignant melanoma of the head and neck. *Acta oto-laryngologica*. 2002;122(8):900-906.
368. Penel N, Mallet Y, Mirabel X, et al. Primary mucosal melanoma of head and neck: prognostic value of clear margins. *Laryngoscope*. 2006;116(6):993-995.
369. Yen CI, Chen HH, Chiang SF, et al. Anorectal melanoma: review of 22 consecutive cases. *Hepatogastroenterology*. 2013;60(121):89-93.
370. Ferraioli D, Lamblin G, Mathevet P, et al. Genital melanoma: prognosis factors and treatment modality. *Archives of Gynecology and Obstetrics*. 2016;294.
371. van Geel AN, den Bakker MA, Kirkels W, et al. Prognosis of primary mucosal penile melano-ma: a series of 19 Dutch patients and 47 patients from the literature. *Urology*. 2007;70(1):143-147.
372. Sánchez-Ortiz R, Huang SF, Tamboli P, Prieto VG, Hester G, Pettaway CA. Melano-ma of the penis, scrotum and male urethra: a 40-year single institution experience. *J Urol*. 2005;173(6):1958-1965.
373. Krengli M, Masini L, Kaanders JHAM, et al. Radiotherapy in the treatment of mucosal me-lanoma of the upper aerodigestive tract: Analysis of 74 cases. A Rare Cancer Network study. *International Journal of Radiation Oncology*Biophysics*. 2006;65(3):751-759.
374. Medina JE, Ferlito A, Pellitteri PK, et al. Current management of mucosal melanoma of the head and neck. *Journal of Surgical Oncology*. 2003;83(2):116-122.
375. Stárek I, Koranda P, Benes P. Sentinel lymph node biopsy: A new perspective in head and neck mucosal melanoma? *Melanoma Res*. 2006;16(5):423-427.
376. Kobayashi K, Ramirez PT, Kim EE, et al. Sentinel node mapping in vulvovaginal melanoma using SPECT/CT lymphoscintigraphy. *Clinical Nuclear Medicine*. 2009;34(12):859-861.
377. Meleti M, Leemans CR, de Bree R, et al. Head and neck mucosal melanoma: experien-ce with 42 patients, with emphasis on the role of postoperative radiotherapy. *Head Neck*. 2008;30(12):1543-1551.
378. Benlyazid A, Thariat J, Temam S, et al. Postoperative radiotherapy in head and neck mucosal melanoma: a GETTEC study. *Arch Otolaryngol Head Neck Surg*. 2010;136(12):1219-1225.
379. Vandenhende C, Leroy X, Chevalier D, Mortuaire G. Sinonasal mucosal melanoma: retro-spective survival study of 25 patients. *J Laryngol Otol*. 2012;126(2):147-151.
380. Temam S, Mamelle G, Marandas P, et al. Postoperative radiotherapy for primary mucosal melanoma of the head and neck. *Cancer*. 2005;103(2):313-319.
381. Nakashima JP, Viégas CM, Fassizoli AL, et al. Postoperative adjuvant radiation therapy in the treatment of primary head and neck mucosal melanomas. *ORL J Otorhinolaryngol Relat Spec*. 2008;70(6):344-351.
382. Owens JM, Roberts DB, Myers JN. The role of postoperative adjuvant radiation therapy in the treatment of mucosal melanomas of the head and neck region. *Arch Otolaryngol Head Neck Surg*. 2003;129(8):864-868.
383. Saigal K, Weed DT, Reis IM, et al. Mucosal Melanomas of the Head and Neck: The Role of Postoperative Radiation Therapy. *ISRN Oncology*. 2012;2012:1-7.
384. Li W, Yu Y, Wang H, et al. Evaluation of the prognostic impact of postoperative adjuvant ra-diotherapy on head and neck mucosal melanoma: a meta-analysis. *BMC Cancer*. 2015;15:758.
385. Wushou A, Hou J, Zhao YJ, et al. Postoperative adjuvant radiotherapy improves loco-regional recurrence of head and neck mucosal melanoma. *Journal of Cranio-Maxillofacial Surgery*. 2015;43(4):553-558.
386. D'Angelo SP, Larkin J, Sosman JA, et al. Efficacy and Safety of Nivolumab Alone or in Com-bination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis. *J Clin Oncol*. 2017;35(2):226-235.
387. Vecchio MD, Guardo LD, Ascierto PA, et al. Efficacy and safety of ipilimumab 3 mg/kg in patients with pretreated, metastatic, mucosal melanoma. *European journal of cancer & clinical oncology*. 2014;50(1):121-127.
388. Postow MA, Luke JJ, Bluth MJ, et al. Ipilimumab for Patients With Advanced Mucosal Mela-noma. *The Oncologist*. 2013;18(6):726-732.
389. Shoushtari AN, Munhoz RR, Kuk D, et al. The efficacy of anti-PD-1 agents in acral and mu-cosal melanoma. *Cancer*. 2016;122(21):3354-3362.
390. Zimmer L, Eigentler T, Kiecker F, et al. Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma. *Journal of Translational Medicine*. 2015;13:1-11.
391. Shoushtari A, Wagstaff J, Ascierto P, et al. CheckMate 067: Long-Term Outcomes in Patients with Mucosal Melanoma. Vol 38.; 2020:10019.
392. Ugurel S, Hildenbrand R, Zimpfer A, et al. Lack of clinical efficacy of imatinib in metastatic melanoma. *Br J Cancer*. 2005;92(8):1398-1405.
393. Wyman K, Atkins MB, Prieto V, et al. Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma. *Cancer*. 2006;106(9):2005-2011.
394. Kim KB, Eton O, Davis DW, et al. Phase II trial of imatinib mesylate in patients with metastatic melanoma. *Br J Cancer*. 2008;99(5):734-740.
395. Quintás-Cardama A, Lazar AJ, Woodman SE, et al. Complete response of stage IV anal mu-cosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib. *Nat Clin Pract Oncol*. 2008;5(12):737-740.
396. Woodman SE, Trent JC, Stemke-Hale K, et al. Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates. *Mol Cancer Ther*. 2009;8(8):2079-2085.
397. Poo-Hwu WJ, Ariyan S, Lamb L, et al. Follow-up recommendations for patients with American Joint Committee on Cancer Stages I-III malignant melanoma. *Cancer*. 1999;86(11):2252-2258.
398. Trotter SC, Sroa N, Winkelmann RR, Olencki T, Bechtel M. A Global Review of Melanoma Follow-up Guidelines. *J Clin Aesthet Dermatol*. 2013;6(9):18-26.
399. Baughan CA, Hall VL, Leppard BJ, Perkins PJ. Follow-up in stage I cutaneous malignant melanoma: An audit. *Clinical Oncology*. 1993;5(3):174-180.
400. Dicker TJ, Kavanagh GM, Herd RM, et al. A rational approach to melanoma follow-up in patients with primary cutaneous melanoma. Scottish Melanoma Group. *Br J Dermatol*. 1999;140(2):249-254.
401. Coit DG, Thompson JA, Algazi A, et al. NCCN Guidelines Insights: Melanoma, Version 3.2016. *J Natl Compr Canc Netw*. 2016;14(8):945-958.
402. Dummer R, Hauschild A, Guggenheim M, Jost L, Pentheroudakis G, ESMO Guidelines Wor-king Group. Melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and fo-llow-up. *Ann Oncol*. 2010;21 Suppl 5:v194-197.
403. Bichakjian CK, Halpern AC, Johnson TM, et al. Guidelines of care for the management of primary cutaneous melanoma. American Academy of Dermatology. *J Am Acad Dermatol*. 2011;65(5):1032-1047.
404. Rychetnik L, Morton RL, McCaffery K, et al. Shared care in the follow-up of early-stage melanoma: a qualitative study of Australian melanoma clinicians' perspectives and models of care. *BMC Health Services Research*. 2012;12(1):468.
405. DiFronzo LA, Wanek LA, Morton DL. Earlier diagnosis of second primary melanoma confirms the benefits of patient education and routine postoperative follow-up. *Cancer*. 2001;91(8):1520-1524.

406. Francken A, Hoekstra H, Francken AB, et al. Follow-up in patients with localised primary cutaneous melanoma. *Lancet Oncol* 6: 608-621. The lancet oncology. 2005;6:608-621.
407. Goggins WB, Tsao H. A population-based analysis of risk factors for a second primary cutaneous melanoma among melanoma survivors. *Cancer*. 2003;97(3):639-643.
408. Johnson TM, Hamilton T, Lowe L. Multiple primary melanomas. *J Am Acad Dermatol*. 1998;39(3):422-427.
409. Kang S, Barnhill RL, Mihm Jr. MC, Sober AJ. Multiple primary cutaneous melanomas. *Cancer*. 1992;70(7):1911-1916.
410. Leiter U, Buettner PG, Eigentler TK, et al. Hazard rates for recurrent and secondary cutaneous melanoma: An analysis of 33,384 patients in the German Central Malignant Melanoma Registry. *Journal of the American Academy of Dermatology*. 2012;66(1):37-45.
411. Stucky CCH, Gray RJ, Dueck AC, et al. Risk factors associated with local and in-transit recurrence of cutaneous melanoma. *Am J Surg*. 2010;200(6):770-774; discussion 774-775.
412. Maroti M, Ulf E, Lyth J, Falkmer U. A prospective population-based study, aiming to support decision-making in a follow-up programme for patients with cutaneous malignant melanoma, based on patterns of recurrence. *European Journal of Dermatology*. 636135552000000000;26(6):586-591.
413. Jones EL, Jones TS, Pearlman NW, et al. Long-term follow-up and survival of patients following a recurrence of melanoma after a negative sentinel lymph node biopsy result. *JAMA Surg*. 2013;148(5):456-461.
414. Elsaesser O, Leiter U, Buettner P, et al. Prognosis of Sentinel Node Staged Patients with Primary Cutaneous Melanoma. *PloS one*. 2012;7:e29791.
415. Brobeil A, Rapaport D, Wells K, et al. Multiple primary melanomas: Implications for screening and follow-up programs for melanoma. *Annals of Surgical Oncology*. 1997;4(1):19-23.
416. Hohnheiser AM, Gefeller O, Göhl J, et al. Malignant melanoma of the skin: long-term follow-up and time to first recurrence. *World J Surg*. 2011;35(3):580-589.
417. Francken AB, Shaw HM, Accortt NA, et al. Detection of First Relapse in Cutaneous Melanoma Patients: Implications for the Formulation of Evidence-Based Follow-up Guidelines. *Ann Surg Oncol*. 2007;14(6):1924-1933.
418. Fusi S, Ariyan S, Sternlicht A. Data on First Recurrence after Treatment for Malignant Melanoma in a Large Patient Population. *Plastic and Reconstructive Surgery*. 1993;91(1):94-98.
419. Kelly JW, Blois MS, Sagebiel RW. Frequency and duration of patient follow-up after treatment of a primary malignant melanoma. *J Am Acad Dermatol*. 1985;13(5 Pt 1):756-760.
420. Martini L, Brandani P, Chiarugi C, Reali UM. First Recurrence Analysis of 840 Cutaneous Melanomas: A Proposal for a Follow-Up Schedule. *Tumori*. 1994;80(3):188-197.
421. Zogakis TG, Essner R, Wang H jing, et al. Natural History of Melanoma in 773 Patients with Tumor-Negative Sentinel Lymph Nodes. *Ann Surg Oncol*. 2007;14(5):1604-1611.
422. Romano E, Scordo M, Dusza SW, et al. Site and timing of first relapse in stage III melanoma patients: implications for follow-up guidelines. *J Clin Oncol*. 2010;28(18):3042-3047.
423. Rueth NM, Groth SS, Tuttle TM, et al. Conditional Survival After Surgical Treatment of Melanoma: An Analysis of the Surveillance, Epidemiology, and End Results Database. *Ann Surg Oncol*. 2010;17(6):1662-1668.
424. Garbe C, Paul A, Kohler-Späth H, et al. Prospective Evaluation of a Follow-Up Schedule in Cutaneous Melanoma Patients: Recommendations for an Effective Follow-Up Strategy. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2003;21:520-529.
425. Moloney FJ, Guitera P, Coates E, et al. Detection of Primary Melanoma in Individuals at Extreme High Risk: A Prospective 5-Year Follow-up Study. *JAMA Dermatology*. 2014;150(8):819-827.
426. Ferrone CR, Ben Porat L, Panageas KS, et al. Clinicopathological features of and risk factors for multiple primary melanomas. *JAMA*. 2005;294(13):1647-1654.
427. Dancey A, Rayatt S, Courthold J, Roberts J. Views of UK melanoma patients on routine follow-up care. *British Journal of Plastic Surgery*. 2005;58(2):245-250.
428. Murchie P, Nicolson MC, Hannaford PC, et al. Patient satisfaction with GP-led melanoma follow-up: a randomised controlled trial. *Br J Cancer*. 2010;102(10):1447-1455.
429. Rychetnik L, McCaffery K, Morton RL, et al. Follow-up of early stage melanoma: Specialist clinician perspectives on the functions of follow-up and implications for extending follow-up intervals. *Journal of Surgical Oncology*. 2013;107(5):463-468.
430. Mitchell J, Callaghan P, Street J, et al. The Experience of Melanoma Follow-Up Care: An Online Survey of Patients in Australia. *Journal of Skin Cancer*. 2014;2014:e429149.
431. Livingstone E, Krajewski C, Eigentler TK, et al. Prospective evaluation of follow-up in melanoma patients in Germany - results of a multicentre and longitudinal study. *Eur J Cancer*. 2015;51(5):653-667.
432. Francken AB, Accortt NA, Shaw HM, et al. Follow-up schedules after treatment for malignant melanoma. *BJS (British Journal of Surgery)*. 2008;95(11):1401-1407.
433. Francken AB, Thompson JF, Bastiaannet E, Hoekstra HJ. Detection of the first recurrence in patients with melanoma: three quarters by the patient, one quarter during outpatient follow-up. *Ned Tijdschr Geneesk*. 2008;152(10):557-562.
434. Podlipnik S, Carrera C, Sánchez M, et al. Performance of diagnostic tests in an intensive follow-up protocol for patients with American Joint Committee on Cancer (AJCC) stage IIB, IIC, and III localized primary melanoma: A prospective cohort study. *Journal of the American Academy of Dermatology*. 2016;75(3):516-524.
435. Watts CG, Dieng M, Morton RL, et al. Clinical practice guidelines for identification, screening and follow-up of individuals at high risk of primary cutaneous melanoma: a systematic review. *British Journal of Dermatology*. 2015;172(1):33-47.
436. National Institute for Health and Clinical Excellence. Improving outcomes for people with skin tumours including melanoma. The Manual. Published online 2006.
437. Idorn LW, Datta P, Heydenreich J, et al. A 3-year follow-up of sun behavior in patients with cutaneous malignant melanoma. *JAMA Dermatology*. 2014;150(2):163-168.
438. Murchie P, Hannaford PC, Wyke S, et al. Designing an integrated follow-up programme for people treated for cutaneous malignant melanoma: a practical application of the MRC framework for the design and evaluation of complex interventions to improve health. *Family Practice*. 2007;24(3):283-292.
439. Scally CP, Wong SL. Intensity of Follow-Up After Melanoma Surgery. *Ann Surg Oncol*. 2014;21(3):752-757.
440. McCarthy WH, Shaw HM, Thompson JF, Milton GW. Time and frequency of recurrence of cutaneous stage I malignant melanoma with guidelines for follow-up study. *Surg Gynecol Obstet*. 1988;166(6):497-502.
441. Hengge UR, Wallerand A, Stutzki A, Kockel N. Cost-effectiveness of reduced follow-up in malignant melanoma. *JDDG: Journal der Deutschen Dermatologischen Gesellschaft*. 2007;5(10):898-907.
442. Leiter U, Marghoob AA, Lasithiotakis K, et al. Costs of the detection of metastases and follow-up examinations in cutaneous melanoma. *Melanoma Research*. 2009;19(1):50-57.
443. Bassères N, Grob JJ, Richard MA, et al. Cost-effectiveness of surveillance of stage I melanoma. A retrospective appraisal based on a 10-year experience in a dermatology department in France. *Dermatology*. 1995;191(3):199-203.
444. Turner RM, Bell KJL, Morton RL, et al. Optimizing the Frequency of Follow-Up Visits for Patients Treated for Localized Primary Cutaneous Melanoma. *JCO*. 2011;29(35):4641-4646.
445. Leiter U. Follow-up of cutaneous melanoma: Stage-dependent hazard rates of recurrence and coupled melanoma. *Journal Der Deutschen Dermatologischen Gesellschaft*. 2009;(7):166-167.
446. Rutkowski P, Lugowska I. Follow-up in melanoma patients. *Memo*. 2014;7(2):83-86.
447. Wevers KP, Hoekstra-Weebers JEHM, Speijers MJ, et al. Cutaneous melanoma: Medical specialists' opinions on follow-up and sentinel lymph node biopsy. *European Journal of Surgical Oncology (EJSO)*. 2014;40(10):1276-1283.
448. Salama AKS, de Rosa N, Scheri RP, et al. Hazard-Rate Analysis and Patterns of Recurrence in Early Stage Melanoma: Moving towards a Rationally Designed Surveillance Strategy. *Slo-minski AT, ed. PLoS ONE*. 2013;8(3):e57665.
449. Martinez LS, Schwartz JS, Freres D, et al. Patient-clinician information engagement increases treatment decision satisfaction among cancer patients through feeling of being informed. *Patient Educ Couns*. 2009;77(3):384-390.
450. Husson O, Holterhues C, Mols F, et al. Melanoma survivors are dissatisfied with perceived information about their diagnosis, treatment and follow-up care. *British Journal of Dermatology*. 2010;163(4):879-881.
451. Johnson RC, Fenn NJ, Horgan K, Mansel RE. Follow-up of patients with a thin melanoma. *Br J Surg*. 1999;86(5):619-621.

452. DiFronzo LA, Wanek LA, Elashoff R, Morton DL. Increased incidence of second primary melanoma in patients with a previous cutaneous melanoma. *Ann Surg Oncol*. 1999;6(7):705-711.
453. Voit C, Mayer T, Kron M, et al. Efficacy of ultrasound B-scan compared with physical examination in follow-up of melanoma patients. *Cancer*. 2001;91(12):2409-2416.
454. Egberts F, Hitschler WN, Weichenthal M, Hauschild A. Prospective monitoring of adjuvant treatment in high-risk melanoma patients: lactate dehydrogenase and protein S-100B as indicators of relapse. *Melanoma Res*. 2009;19(1):31-35.
455. Garbe C, Leiter U, Ellwanger U, et al. Diagnostic value and prognostic significance of protein S-100 β , melanoma-inhibitory activity, and tyrosinase/MART-1 reverse transcription-polymerase chain reaction in the follow-up of high-risk melanoma patients. *Cancer*. 2003;97(7):1737-1745.
456. Schlagenhauff B, Schitteck B, Ellwanger U, et al. Significance of serum protein S100 levels in screening for melanoma metastasis: does protein S100 enable early detection of melanoma recurrence? *Melanoma Res*. 2000;10(5):451-459.
457. Brown RE, Stromberg AJ, Hagendoorn LJ, et al. Surveillance after surgical treatment of melanoma: Futility of routine chest radiography. *Surgery*. 2010;148(4):711-717.
458. Morton RL, Craig JC, Thompson JF. The role of surveillance chest X-rays in the follow-up of high-risk melanoma patients. *Annals of Surgical Oncology*. 2009;16(3):571-577.
459. Cromwell KD, Ross MI, Xing Y, et al. Variability in melanoma post-treatment surveillance practices by country and physician specialty: A systematic review. *Melanoma Research*. 2012;22(5):376-385.
460. Rinne D, Baum RP, Hör G, Kaufmann R. Primary staging and follow-up of high risk melanoma patients with whole-body 18F-fluorodeoxyglucose positron emission tomography: results of a prospective study of 100 patients. *Cancer*. 1998;82(9):1664-1671.
461. Kaufmann PM, Crone-Münzebrock W. Tumor follow-up using sonography and computed tomography in the abdominal region of patients with malignant melanoma. *Aktuelle Radiol*. 1992;2(2):81-85.
462. Hausmann D, Jochum S, Utikal J, et al. Comparison of the diagnostic accuracy of whole-body MRI and whole-body CT in stage III/IV malignant melanoma. *JDDG: Journal der Deutschen Dermatologischen Gesellschaft*. 2011;9(3):212-221.
463. DeRose ER, Pleet A, Wang W, et al. Utility of 3-year torso computed tomography and head imaging in asymptomatic patients with high-risk melanoma. *Melanoma Res*. 2011;21(4):364-369.
464. Strobel K, Dummer R, Husarik DB, et al. High-Risk Melanoma: Accuracy of FDG PET/CT with Added CT Morphologic Information for Detection of Metastases. *Radiology*. 2007;244(2):566-574.
465. Poklepovic AS, Luke JJ. Considering adjuvant therapy for stage II melanoma. *Cancer*. 2020;126(6):1166-1174.
466. Garbe C, Keim U, Amaral T, et al.; Central Malignant Melanoma Registry (CMMR). Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment. *J Clin Oncol*. 2022;40(32):3741-3749.
467. Lee AY, Droppelmann N, Panageas KS, et al. Patterns and Timing of Initial Relapse in Pathologic Stage II Melanoma Patients. *Ann Surg Oncol*. 2017;24(4):939-946.
468. Luke JJ, et al. Pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: Final analysis of distant metastasis-free survival in the phase 3 KEYNOTE-716 study. *JCO* 41, LBA9505-LBA9505(2023).
469. Kirkwood JM, Del Vecchio M, Weber J, et al. Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial. *Nat Med*. 2023;29(11):2835-2843.
470. Long GV, Luke JJ, Khatkhat MA, et al.; KEYNOTE-716 Investigators. Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial. *Lancet Oncol*. 2022;23(11):1378-1388.
471. van Akkooi AC, Hauschild A, Long GV, et al. COLUMBUS-AD: phase III study of adjuvant encorafenib + binimetinib in resected stage IIB/IIC BRAF V600-mutated melanoma. *Future Oncol*. 2023;19(30):2017-2027.
472. Eggermont AMM, Kicinski M, et al. Five-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III Melanoma. *NEJM Evid*. 2022;1(11):EVIDoA2200214.
473. Larkin J, Del Vecchio M, Mandalá M, et al. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238. *Clin Cancer Res*. 2023;29(17):3352-3361.
474. Wilmott JS, Tawbi H, Engh JA, et al. Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases. *Clin Cancer Res*. 2023;29(3):521-531.
475. Marquez-Rodas I, Arance Fernandez AM, Berciano Guerrero MA, et al. Encorafenib and binimetinib followed by radiotherapy for patients with symptomatic BRAF mutated melanoma brain metastases: GEM1802/E-BRAIN clinical trial.
476. Robert C, Carlino MS, McNeil C, Ribas A, et al. Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma. *J Clin Oncol*. 2023;41(24):3998-4003.
477. Long GV, Stephen Hodi F, Lipson EJ, et al. Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma. *NEJM Evid*. 2023;2(4):EVIDoA2200239.
478. Halaška MJ, Rob F et al. *Onkologická onemocnění během těhotenství*. Praha: Mladá fronta; 2015.
479. Pereg D, Koren G, Lishner M. Cancer in pregnancy: gaps, challenges and solutions. *Cancer Treat Rev*. 2008;34(4):302-12.
480. Stensheim H, Møller B, van Dijk T, Fosså SD. Cause-specific survival for women diagnosed with cancer during pregnancy or lactation: a registry-based cohort study. *J Clin Oncol*. 2009;27(1):45-51.
481. Lee YY, Roberts CL, Dobbins T, et al. Incidence and outcomes of pregnancy-associated cancer in Australia, 1994-2008: a population-based linkage study. *BJOG*. 2012 Dec;119(13):1572-82.
482. Watson M, Geller AC, Tucker MA, et al. Melanoma burden and recent trends among non-Hispanic whites aged 15-49 years, United States. *Prev Med*. 2016;91:2940-298.
483. Weir HK, Marrett LD, Cokkinides V, et al. Melanoma in adolescents and young adults (ages 15-39 years): United States, 1999-2006. *J Am Acad Dermatol*. 2011;65(5 Suppl 1):S38-49.
484. Garbe C, Amaral T, Peris K; European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO), and the European Organization for Research and Treatment of Cancer (EORTC). European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022. *Eur J Cancer*. 2022;170:256-284.
485. Andersson TM, Johansson AL, Fredriksson I, Lambe M. Cancer during pregnancy and the postpartum period: A population-based study. *Cancer*. 2015;121(12):2072-7.
486. Carter TJ, George C, Harwood C, Nathan P. Melanoma in pregnancy: Diagnosis and management in early-stage and advanced disease. *Eur J Cancer*. 2022;166:240-253.
487. Morton SK, Morton AP. Melanoma and pregnancy. *Australas J Dermatol*. 2017;58(4):259-267.
488. Ellis DL, Wheeland RG. Increased nevus estrogen and progesterone ligand binding related to oral contraceptives or pregnancy. *J Am Acad Dermatol*. 1986 Jan;14(1):25-31.
489. Kumari R, Jaisankar TJ, Thappa DM. A clinical study of skin changes in pregnancy. *Indian J Dermatol Venereol Leprol*. 2007 Mar-Apr;73(2):141.
490. Vora RV, Gupta R, Mehta MJ, et al. Pregnancy and skin. *J Family Med Prim Care*. 2014 Oct-Dec;3(4):318-24.
491. Tyler KH. Physiological skin changes during pregnancy. *Clin Obstet Gynecol*. 2015 Mar;58(1):119-24.
492. Karagas MR, Zens MS, Stukel TA, et al. Pregnancy history and incidence of melanoma in women: a pooled analysis. *Cancer Causes Control*. 2006 Feb;17(1):11-9.
493. Bannister-Tyrrell M, Roberts CL, Hasovits C, et al. Incidence and outcomes of pregnancy-associated melanoma in New South Wales 1994-2008. *Aust N Z J Obstet Gynaecol*. 2015 Apr;55(2):116-22.
494. Khosrotehrani K, Nguyen Huu S, Prignon A, et al. Pregnancy promotes melanoma metastasis through enhanced lymphangiogenesis. *Am J Pathol*. 2011 Apr;178(4):1870-80.
495. Dadras SS, Lange-Asschenfeldt B, Velasco P, et al. Tumor lymphangiogenesis predicts melanoma metastasis to sentinel lymph nodes. *Mod Pathol*. 2005 Sep;18(9):1232-42.
496. Costanzo V, Bardelli A, Siena S, Abignani S. Exploring the links between cancer and placenta development. *Open Biol*. 2018 Jun;8(6):180081.

497. Sedlmayr P, Blaschitz A. Placental expression of indoleamine 2,3-dioxygenase. *Wien Med Wochenschr.* 2012 May;162(9-10):214-9.
498. Abumaree MH, Chamley LW, Badri M, El-Muzaini MF. Trophoblast debris modulates the expression of immune proteins in macrophages: a key to maternal tolerance of the fetal allograft? *J Reprod Immunol.* 2012 Jun;94(2):131-41.
499. Panfili E, Mondanelli G, Orabona C, et al. The catalytic inhibitor epacadostat can affect the non-enzymatic function of IDO1. *Front Immunol.* 2023 Apr 14;14:1134551.
500. de Giorgi V, Gori A, Grazzini M, et al. Estrogens, estrogen receptors and melanoma. *Expert Rev Anticancer Ther.* 2011 May;11(5):739-47.
501. Chapman PB, Einhorn LH, Meyers ML, et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. *J Clin Oncol.* 1999 Sep;17(9):2745-51.
502. Beguerie JR, Xingzhong J, Valdez RP. Tamoxifen vs. non-tamoxifen treatment for advanced melanoma: a meta-analysis. *Int J Dermatol.* 2010 Oct;49(10):1194-202.
503. Karagas MR, Zens MS, Stukel TA, et al. Pregnancy history and incidence of melanoma in women: a pooled analysis. *Cancer Causes Control.* 2006 Feb;17(1):11-9.
504. Byrom L, Olsen C, Knight L, et al. Increased mortality for pregnancy-associated melanoma: systematic review and meta-analysis. *J Eur Acad Dermatol Venereol.* 2015 Aug;29(8):1457-66.
505. Kyrgidis A, Lallas A, Moscarella E, et al. Does pregnancy influence melanoma prognosis? A meta-analysis. *Melanoma Res.* 2017 Aug;27(4):289-299.
506. Jones MS, Lee J, Stern SL, Faries MB. Is Pregnancy-Associated Melanoma Associated with Adverse Outcomes? *J Am Coll Surg.* 2017 Jul;225(1):149-158.
507. Lens MB, Rosdahl I, Ahlbom A, et al. Effect of pregnancy on survival in women with cutaneous malignant melanoma. *J Clin Oncol.* 2004 Nov 1;22(21):4369-75.
508. Martires KJ, Stein JA, Grant-Kels JM, Driscoll MS. Meta-analysis concerning mortality for pregnancy-associated melanoma. *J Eur Acad Dermatol Venereol.* 2016 Oct;30(10):e107-e108.
509. Slingsluff CL Jr, Reintgen DS, Vollmer RT, Seigler HF. Malignant melanoma arising during pregnancy. A study of 100 patients. *Ann Surg.* 1990 May;211(5):552-7; discussion 558-9.
510. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. *J Clin Oncol.* 2001 Aug 15;19(16):3622-34.
511. Cosgarea I, Trevisan-Herraz M, Ungureanu L, Zalaudek I. Dermatoscopic Features of Naevi During Pregnancy-A Mini Review. *Front Med (Lausanne).* 2021 Aug 9;8:727319.
512. Martins-Costa GM, Bakos R. Total Body Photography and Sequential Digital Dermoscopy in Pregnant Women. *Dermatol Pract Concept.* 2019 Apr 30;9(2):126-131.
513. Strumia R. Digital epiluminescence microscopy in nevi during pregnancy. *Dermatology.* 2002;205(2):186-7.
514. Rubegni P, Sbrano P, Burrioni M, et al. Melanocytic skin lesions and pregnancy: digital dermoscopy analysis. *Skin Res Technol.* 2007 May;13(2):143-7.
515. Aktürk AS, Bilen N, Bayrängürler D, et al. Dermoscopy is a suitable method for the observation of the pregnancy-related changes in melanocytic nevi. *J Eur Acad Dermatol Venereol.* 2007 Sep;21(8):1086-90.
516. Mossman KL, Hill LT. Radiation risks in pregnancy. *Obstet Gynecol.* 1982 Aug;60(2):237-42. PMID: 6760010.
517. Wrixon AD. New recommendations from the International Commission on Radiological Protection--a review. *Phys Med Biol.* 2008 Apr 21;53(8):R41-60.
518. ACR-SPR practice parameter for imaging pregnant or potentially pregnant patients with ionizing radiation. Practice Parameter revised 2023; Resolution 31; <https://www.acr.org/-/media/acr/files/practice-parameters/pregnant-pts.pdf>
519. Wall BF, Meara JR, Muirhead CR, et al. Protection of pregnant patients during diagnostic medical exposures to ionising radiation: advice from the Health Protection Agency, the Royal College of Radiologists and the College of Radiographers. Documents of the Health Protection Agency: Radiation, Chemical and Environmental Hazards; 2009
520. McCollough CH, Schueler BA, Atwell TD, et al. Radiation exposure and pregnancy: when should we be concerned? *Radiographics.* 2007 Jul-Aug;27(4):909-17; discussion 917-8.
521. Hatem A, Azim Jr., Managing Cancer During Pregnancy, Springer, 2016, chapter 2: Staging Workup in Pregnant Cancer Patients, Ailbhe C. O'Neill, Pamela J. DiPiro, and Erica L. Mayer, p. 17-28.
522. Eskandar O, Eckford S, Watkinson T. Safety of diagnostic imaging in pregnancy. Part 1: X-ray, nuclear medicine investigations, computed tomography and contrast media. *Obstet Gynaecol.* 2010;12(2):71e8.
523. Patel SJ, Reede DL, Katz DS, et al. Imaging the pregnant patient for nonobstetric conditions: algorithms and radiation dose considerations. *Radiographics.* 2007 Nov-Dec;27(6):1705-22.
524. Kennedy EV, Iball GR, Brett DS. Investigation into the effects of lead shielding for fetal dose reduction in CT pulmonary angiography. *Br J Radiol.* 2007 Aug;80(956):631-8.
525. Lum M, Tsiouris AJ. MRI safety considerations during pregnancy. *Clin Imaging.* 2020 Jun;62:69-75.
526. De Wilde JP, Rivers AW, Price DL. A review of the current use of magnetic resonance imaging in pregnancy and safety implications for the fetus. *Prog Biophys Mol Biol.* 2005 Feb-Apr;87(2-3):335-53.
527. Chang ST, Desser TS, Gayer G, Menias CO. Metastatic melanoma in the chest and abdomen: the great radiologic imitator. *Semin Ultrasound CT MR.* 2014;35:272-89.
528. Pfannenberger C, Aschoff P, Schanz S, et al. Prospective comparison of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced malignant melanoma. *Eur J Cancer.* 2007; 43:557-64.
529. Cohen-Kerem R, Railton C, Oren D, et al. Pregnancy outcome following non-obstetric surgical intervention. *Am J Surg.* 2005;190:467.
530. Moore HB, Juarez-Colunga E, Bronsert M, et al. Effect of pregnancy on adverse outcomes after general surgery. *JAMA Surg.* 2015;150:637-43.
531. Borsari S, Longo C. Melanoma staging. In: *Cutaneous melanoma.* Elsevier; 2017. p. 81-90.
532. Leachman SA, Jackson R, Eliason MJ, et al. Management of Melanoma During Pregnancy. *Dermatology Nursing.* 2007;19(2):145-152,161.
533. Borges V, Puig S, Malvey J, et al. Nevus, melanoma y embarazo. *Actas Dermosifiliogr.* 2011;102:650-657.
534. Kouba DJ, LoPiccolo MC, Alam M, et al. Guidelines for the use of local anesthesia in office-based dermatologic surgery. *J Am Acad Dermatol.* 2016 Feb 27. pii:S0190-9622(16)00074-8.
535. El Sharouni MA, et al. Time interval between diagnostic excision-biopsy of a primary melanoma and sentinel node biopsy: effects on the sentinel node positivity rate and survival outcomes. *Eur J Cancer.* 2022 May;167:123-132.
536. Ariyan S, Ali-Salaam P, Cheng DW, Truini C. Reliability of lymphatic mapping after wide local excision of cutaneous melanoma. *Ann Surg Oncol.* 2007; 14:2377-2383. [PubMed: 17541771]
537. Broer N, Buonocore S, Goldberg C, et al. A Proposal for the Timing of Management of Patients with Melanoma Presenting During Pregnancy. *J Surg Oncol.* 2012 July 1;106(1):36-40.
538. Bello DM, Faries MB. The Landmark Series: MSLT-1, MSLT-2 and DeCOG (Management of Lymph Nodes). *Ann Surg Oncol.* 2020 Jan;27(1):15-21.
539. Mondini MM, Cuenca RE, Ollila DW, et al. Sentinel lymph node biopsy during pregnancy, initial clinical experience. *Ann Surg Oncol.* 2007;14(1):218-21.
540. Peccatori FA, Azim HA Jr, Orecchia R, et al. Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. ESMO Guidelines Working Group. *Ann Oncol.* 2013 Oct;24 Suppl 6:vi160-70. Epub 2013 Jun 27.
541. Schwartz JL, Mozurkewich EL, Johnson TM. Current management of patients with melanoma who are pregnant, want to get pregnant, or do not want to get pregnant. *Cancer.* 2003;97:2130.
542. Gropper AB, Calvillo KZ, Dominici L, et al. Sentinel lymph node biopsy in pregnant women with breast cancer. *Ann Surg Oncol.* 2014;21(8):2506-11.
543. Andtbacka RH, Donaldson MR, Bowles TL, et al. Sentinel lymph node biopsy for melanoma in pregnant women. *Ann Surg Oncol.* 2013 Feb;20(2):689-96.
544. Moody JA, Ali RF, Carbone AC, et al. Complications of sentinel lymph node biopsy for melanoma - A systematic review of the literature. *Eur J Surg Oncol.* 2017 Feb;43(2):270-277.
545. Adelstein JS, et al. Administered radionuclides in pregnancy. April 1999, *Teratology* 59(4):236-9.
546. Faries MB, Thompson JF, Cochran AJ, et al. Completion dissection or observation for sentinel-node metastasis in melanoma. *N Engl J Med.* 2017;376(23):2211-22.
547. Leiter U, Stadler R, Mauch C, et al. Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. *Lancet Oncol.* 2016;17(6):757-67.

548. Leiter U, Stadler R, Mauch C, et al. Final analysis of DECOG-SLT trial: survival outcomes of complete lymph node dissection in melanoma patients with positive sentinel node. (Abstract). *J Clin Oncol*. 2018;36(15):9501.
549. Crisan D, Nicolai, Treiber N, et al. Surgical treatment of melanoma in pregnancy: a practical guideline, Deutsche Dermatologische Gesellschaft (DDG). Published by John Wiley & Sons Ltd. | JDDG | 1610-0379/2016/1406.
550. Potter JF, Scheoneman M. Metastasis of Maternal cancer to the placenta and fetus. *Cancer* 1970;25:380-388.
551. Dildy GA, Moise KJ, Carpenter RJ, Kilma T. Maternal malignancy metastatic to the products of conception: a review. *Obstet Gynecol Surv*. 1988;44:535-540.
552. Jackish C, Louween F, Schwenkagen A, et al. Lung cancer during pregnancy involving the products of conception and a review of the literature. *Arch Gynecol Obstet*. 2003;268:69-77.
553. Alexander A, et al. Metastatic melanoma in pregnancy: risk of transplacental metastases in the in-fant. *J Clin Oncol* 2003;21(11): 2179e86.
554. Wiedemann SV, et al. CLAUDIUS Study: Risk of materno-fetal transmission of melanoma cells in pregnant women with high grade melanoma – A retrospective multicenter study and literature review. *EJC Skin Cancer*. 2023; vol. 1, 100005, ISN 2772-6118, <https://doi.org/10.1016/j.ejcskn.2023.100005>.
555. Driscoll MS, Grant-Kels JM, et al. Hormones, nevi, and melanoma: an approach to the patient. *Am Acad Dermatol*. 2007;57(6):919.
556. Driscoll MS, Martires K, Kalowitz Bieber A, et al. Pregnancy and melanoma. *J Am Acad Dermatol* 2016;75:669-78.
557. Chang AE, Karnell LH, Menck HR. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. *Cancer*. 1998 Oct 15;83(8):1664-78.
558. Carvajal RD, Schwartz GK, Tezel T, et al. Metastatic disease from uveal melanoma: treatment options and future prospects. *Br J Ophthalmol*. 2017 Jan;101(1):38-44.
559. Bataille V, Sasieni P, Cuzick J, et al. Risk of ocular melanoma in relation to cutaneous and iris naevi. *Int J Cancer*. 1995 Mar 3;60(5):622-6.
560. Egan KM, Seddon JM, Glynn RJ, et al. Epidemiologic aspects of uveal melanoma. *Surv Ophthalmol*. 1988 Jan-Feb;32(4):239-51.
561. Shah CP, Weis E, Lajous M, et al. Intermittent and chronic ultraviolet light exposure and uveal melanoma: a meta-analysis. *Ophthalmology*. 2005 Sep;112(9):1599-607.
562. Gass JD. Problems in the differential diagnosis of choroidal nevi and malignant melanoma. XXXIII Edward Jackson Memorial lecture. *Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol*. 1977 Jan-Feb;83(1):19-48. PMID: 898474.
563. Augsburger JJ, Schroeder RP, Territo C, et al. Clinical parameters predictive of enlargement of melanocytic choroidal lesions. *Br J Ophthalmol*. 1989 Nov;73(11):911-7.
564. Bai H, Bosch JJ, Heindl LM. Current management of uveal melanoma: A review. *Clin Exp Ophthalmol*. 2023 Jul;51(5):484-494.
565. Ramaiya KJ, Harbour JW. Current management of uveal melanoma. *Expert Review of Ophthalmology*, 2007;2(6):939-946.
566. Factors predictive of growth and treatment of small choroidal melanoma: COMS Report No. 5. The Collaborative Ocular Melanoma Study Group. *Arch Ophthalmol*. 1997 Dec;115(12):1537-44.
567. Shields CL, Furuta M, Berman EL, et al. Choroidal nevus transformation into melanoma: analysis of 2514 consecutive cases. *Arch Ophthalmol*. 2009 Aug;127(8):981-7.
568. Shields CL, Shields JA, Materin M, et al. Iris melanoma: risk factors for metastasis in 169 consecutive patients. *Ophthalmology*. 2001 Jan;108(1):172-8.
569. Harbour JW, Augsburger JJ, Eagle RC Jr. Initial management and follow-up of melanocytic iris tumors. *Ophthalmology*. 1995 Dec;102(12):1987-93.
570. Singh AD, De Potter P, Fijal BA, et al. Lifetime prevalence of uveal melanoma in white patients with oculo(dermal) melanocytosis. *Ophthalmology*. 1998 Jan;105(1):195-8.
571. Freedman MI, Folk JC. Metastatic tumors to the eye and orbit. Patient survival and clinical characteristics. *Arch Ophthalmol*. 1987 Sep;105(9):1215-9.
572. Eskelin S, Pyrhönen S, Summanen P, et al. Tumor doubling times in metastatic malignant melanoma of the uvea: tumor progression before and after treatment. *Ophthalmology*. 2000 Aug;107(8):1443-9.
573. Augsburger JJ, Gamel JW. Clinical prognostic factors in patients with posterior uveal malignant melanoma. *Cancer*. 1990 Oct 1;66(7):1596-600.
574. Seddon JM, Albert DM, Lavin PT, Robinson N. A prognostic factor study of disease-free interval and survival following enucleation for uveal melanoma. *Arch Ophthalmol*. 1983 Dec;101(12):1894-9.
575. Trolet J, Hupé P, Huon I, et al. Genomic profiling and identification of high-risk uveal melanoma by array CGH analysis of primary tumors and liver metastases. *Invest Ophthalmol Vis Sci*. 2009 Jun;50(6):2572-80.
576. Schoenfield L, Pettay J, Tubbs RR, Singh AD. Variation of monosomy 3 status within uveal melanoma. *Arch Pathol Lab Med*. 2009 Aug;133(8):1219-22.
577. Mensink HW, Vaarwater J, Kiliç E, et al. Chromosome 3 intratumor heterogeneity in uveal melanoma. *Invest Ophthalmol Vis Sci*. 2009 Feb;50(2):500-4.
578. Tschentscher F, Prescher G, Zeschneck M, et al. Identification of chromosomes 3, 6, and 8 aberrations in uveal melanoma by microsatellite analysis in comparison to comparative genomic hybridization. *Cancer Genet Cytogenet*. 2000 Oct 1;122(1):13-7.
579. Onken MD, Worley LA, Char DH, et al. Collaborative Ocular Oncology Group report number 1: prospective validation of a multi-gene prognostic assay in uveal melanoma. *Ophthalmology*. 2012 Aug;119(8):1596-603.
580. Worley LA, Onken MD, Person E, et al. Transcriptomic versus chromosomal prognostic markers and clinical outcome in uveal melanoma. *Clin Cancer Res*. 2007 Mar 1;13(5):1466-71.
581. Petrausch U, Martus P, Tönnies H, et al. Significance of gene expression analysis in uveal melanoma in comparison to standard risk factors for risk assessment of subsequent metastases. *Eye (Lond)*. 2008 Aug;22(8):997-1007.
582. Harbour JW, Chen R. The DecisionDx-UM Gene Expression Profile Test Provides Risk Stratification and Individualized Patient Care in Uveal Melanoma. *PLoS Curr*. 2013 Apr 9;5:ecur-rents.eogt.af8ba80fc776c8f1ce8f5dc485d4a618.
583. Bidard FC, Madic J, Mariani P, et al. Detection rate and prognostic value of circulating tumor cells and circulating tumor DNA in metastatic uveal melanoma. *Int J Cancer*. 2014 Mar 1;134(5):1207-13.
584. Schuster R, Bechrakis NE, Stroux A, et al. Prognostic relevance of circulating tumor cells in metastatic uveal melanoma. *Oncology*. 2011;80(1-2):57-62.
585. Skinner CC, Augsburger JJ, Augsburger BD, Correa ZM. Comparison of Alternative Tumor Size Classifications for Posterior Uveal Melanomas. *Invest Ophthalmol Vis Sci*. 2017 Jul 1;58(9):3335-3342.
586. Furney SJ, Pedersen M, Gentien D, et al. SF3B1 mutations are associated with alternative splicing in uveal melanoma. *Cancer Discov*. 2013 Oct;3(10):1122-1129.
587. Van Raamsdonk CD, Bezrookove V, Green G, et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. *Nature*. 2009 Jan 29;457(7229):599-602.
588. Van Raamsdonk CD, Griewank KG, Crosby MB, et al. Mutations in GNA11 in uveal melanoma. *N Engl J Med*. 2010 Dec 2;363(23):2191-9.
589. Onken MD, Worley LA, Long MD, et al, Harbour JW. Oncogenic mutations in GNAQ occur early in uveal melanoma. *Invest Ophthalmol Vis Sci*. 2008 Dec;49(12):5230-4.
590. Shoushtari AN, Carvajal RD. GNAQ and GNA11 mutations in uveal melanoma. *Melanoma Res*. 2014 Dec;24(6):525-34.
591. Feng X, Degese MS, Iglesias-Bartolome R, et al. Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry. *Cancer Cell*. 2014 Jun 16;25(6):831-45.
592. Harbour JW, Onken MD, Roberson ED, et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. *Science*. 2010 Dec 3;330(6009):1410-3.
593. Field MG, Harbour JW. Recent developments in prognostic and predictive testing in uveal melanoma. *Curr Opin Ophthalmol*. 2014 May;25(3):234-9.
594. Finger PT, Kurli M, Reddy S, et al. Whole body PET/CT for initial staging of choroidal melanoma. *Br J Ophthalmol*. 2005 Oct;89(10):1270-4.
595. Jovanovic P, Mihajlovic M, Djordjevic-Jocic J, et al. Ocular melanoma: an overview of the current status. *Int J Clin Exp Pathol*. 2013 Jun 15;6(7):1230-44. PMID: 23826405; PMCID: PMC3693189.
596. Kujala E, Mäkitie T, Kivelä T. Very long-term prognosis of patients with malignant uveal melanoma. *Invest Ophthalmol Vis Sci*. 2003 Nov;44(11):4651-9.

597. Collaborative Ocular Melanoma Study Group. Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS report no. 15. *Arch Ophthalmol*. 2001 May;119(5):670-6.
598. Awh CC, Wilson MW. Symptomatic Liver Metastasis Prompting Diagnosis of Uveal Melanoma. *Ocul Oncol Pathol*. 2020 May;6(3):164-167.
599. Kolandjian NA, Wei C, Patel SP, et al. Delayed systemic recurrence of uveal melanoma. *Am J Clin Oncol*. 2013 Oct;36(5):443-9.
600. Diener-West M, Reynolds SM, Agugliaro DJ, et al.; Collaborative Ocular Melanoma Study Group. Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group Report No. 26. *Arch Ophthalmol*. 2005 Dec;123(12):1639-43.
601. Wei AZ, Uriel M, Porcu A, et al. Characterizing metastatic uveal melanoma patients who develop symptomatic brain metastases. *Front Oncol*. 2022 Sep 8;12:961517.
602. Caminal JM, Lorenzo D, Gutierrez C, et al. Local Resection in Choroidal Melanoma: A Review. *J Clin Med*. 2022 Dec 1;11(23):7156.
603. Augsburger JJ, Corrêa ZM, Freire J, Brady LW. Long-term survival in choroidal and ciliary body melanoma after enucleation versus plaque radiation therapy. *Ophthalmology*. 1998 Sep;105(9):1670-8.
604. Collaborative Ocular Melanoma Study Group. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report No. 28. *Arch Ophthalmol*. 2006 Dec;124(12):1684-93.
605. Stålhammar G, Herrspiegel C. Long-term relative survival in uveal melanoma: a systematic review and meta-analysis. *Commun Med (Lond)*. 2022 Mar 1;2:18.
606. Khoja L, Atenafu EG, Suci S, et al. Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study. *Ann Oncol*. 2019 Aug 1;30(8):1370-1380.
607. Singh AD, Turell ME, Topham AK. Uveal melanoma: trends in incidence, treatment, and survival. *Ophthalmology*. 2011 Sep;118(9):1881-5.
608. Demkowicz P, Pointdujour-Lim R, Miguez S, et al. Determinants of overall survival in patients with metastatic uveal melanoma. *Cancer*. 2023 Oct 15;129(20):3275-3286.
609. Nathan P, Hassel JC, Rutkowski P, et al.; IMCgp100-202 Investigators. Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma. *N Engl J Med*. 2021 Sep 23;385(13):1196-1206.
610. Hassel JC, Piperno-Neumann S, Rutkowski P, et al. Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma. *N Engl J Med*. 2023 Dec 14;389(24):2256-2266.
611. Aaberg TM Jr, Cook RW, Oelschlager K, et al. Current clinical practice: differential management of uveal melanoma in the era of molecular tumor analyses. *Clin Ophthalmol*. 2014 Dec 3;8:2449-60.
612. Gezgin G, Luk SJ, Cao J, et al. PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma. *JAMA Ophthalmol*. 2017 Jun 1;135(6):541-549.
613. Sen M, Demirci H, Honavar SG. Targeted therapy in ophthalmic oncology: The current status. *Asia Pac J Ophthalmol (Phila)*. 2024 Mar-Apr;13(2):100062.
614. Gelmi MC, Jager MJ. Uveal melanoma: Current evidence on prognosis, treatment and potential developments. *Asia Pac J Ophthalmol (Phila)*. 2024 Mar-Apr;13(2):100060.
615. Glezgová J. Nitrooční nádory. In: Heissigerová J. *Oftalmologie*, 3. vydání. Praha: Maxdorf 2023, pp. 279-283.
616. Kimmtrak – Summary of Medicinal Product Characteristics (SmPC), available from: <http://www.sukl.cz/>, <http://www.ema.europa.eu/>
617. Loda A, Semeraro F, Parolini S, Ronca R, Rezzola S. Cancer stem-like cells in uveal melanoma: Novel insights and therapeutic implications. *Biochim Biophys Acta Rev Cancer*. 2024 May 1:189104.
618. Pandiani C, Béranger GE, Leclerc J, et al. Focus on cutaneous and uveal melanoma specificities. *Genes Dev*. 2017 Apr 15;31(8):724-743.